

Author Index

- Abe H, *see* Orita, 727
 Akiyama K, *see* Hashimoto, 805
 Alexander J, *see* Schipke, 481
 Aliberti G, D'Erasmo D, Oddo CM, Vecchi E. Effect of the acute sublingual administration of ketanserin in hypertensive patients, 697
 Amende I, Herrmann G, Simon R, Hood WP Jr., Wenzlaff P, Lichtlen PR. The effects of pretreatment with nitroglycerin on ischemic left ventricular dysfunction during coronary angioplasty, 497
 Amery A, *see* Lijnen, 741
 Antonaccio MJ. Cardiovascular pharmacology (3rd edition), 659
 Antonaccio MJ, *see* Fleming, 763
 Arakawa K. Reply to letter of Dr. R. B. Singh, 158
 Araujo L, *see* Kaski, 991
 Aronson RS, *see* Cranefield, 531
 Ascuitto RJ, *see* Ross-Ascuitto, 1011
 Backes RJ, Gersh BJ. The treatment of coronary artery disease in the elderly, 449
 Bahavar H, *see* Mitrovic, 689
 Banai S, *see* Tzivoni, 505
 Barcikowski B, *see* Ceremuzynski, 643
 Becker LC. Do neutrophils contribute to myocardial stunning?, 909
 Benowitz N, *see* Cheitlin, 719
 Berkenboom G, *see* Bohyn, 457
 Bevilacqua M, Vago T, Norbiato G. Effect of propionyl-L-carnitine on L-type calcium channels in human heart sarcolemma, 31
 Boffa GM, *see* Ferrari, 57
 Bohyn M, Berkenboom G, Fontaine J. Effect of nitrate tolerance and dipyridamole on the response to SIN₁ in the human isolated saphenous vein, 457
 Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overview, 249
 Bolli R, Hartley CJ, Rabinovitz RS. Clinical relevance of myocardial "stunning," 877
 Bolognesi R. The pharmacologic treatment of atrial fibrillation, 617
 Bolukoglu H, Nellis SH, Liedtke AJ. Effects of propionate on mechanical and metabolic performance in aerobic rat hearts, 37
 Boraso A, *see* Ferrari, 17
 Braunwald E. Stunning of the myocardium: an update, 849
 Buchanan JO, *see* Fleming, 763
 Burkhoff D, *see* Schipke, 481
 Burton GW, *see* Mickle, 309
 Byrd R, *see* Cheitlin, 719
 Caillé G, *see* Villière, 997
 Caralis DG, Kyriakides Z, Ioakimides C. Acute hemodynamic effects of molsidomine in patients with ischemic cardiomyopathy, 155
 Cargnoni A, *see* Ferrari, 57
 Cargnoni A, *see* Ferrari, 277
 Ceconi C, *see* Ferrari, 57
 Ceconi C, *see* Ferrari, 277
 Ceremuzynski L, Klos J, Barcikowski B, Herbaczynska-Cedro K. Calcium channel blocker prevents stress-induced activation of renin and aldosterone in conscious pig, 643
 Cerutti G, *see* Cevese, 45
 Cevese A, Schena F, Cerutti G. Short-term hemodynamic effects of intravenous propionyl-L-carnitine in anesthetized dogs, 45
 Champion de Crespigny PC, *see* West, 747
 Chartrand C, *see* Villière, 997
 Cheitlin MD, Byrd R, Benowitz N, Liu E, Modin G. Amiloride improves hemodynamics in patients with chronic congestive heart failure treated with chronic digoxin and diuretics, 719
 Chiddo A, Gagliardi A, Musci S, Troito G, Grimaldi N, Locuratolo N, Rizzon P. Hemodynamic study of intravenous propionyl-L-carnitine in patients with ischemic heart disease and normal left ventricular function, 107
 Clement DL, *see* Duprez, 709
 Condorelli E, *see* Ferrari, 17
 Coronel R, *see* Heijnis, 1035
 Corr PB, *see* Yamada, 67
 Coumel P, *see* Fabiato, 167
 Coumel P, *see* Dessertenne, 171
 Coupez JM, *see* Dupont, 701
 Coupez-Lopinot R, *see* Dupont, 701
 Cranefield PF, Aronson RS. Torsades de pointes and early afterdepolarizations, 531
 Curello S, *see* Ferrari, 57
 Curello S, *see* Ferrari, 277
 Curtis MJ. Torsades de pointes: arrhythmias, syndrome or chimera? A perspective in the light of the Lambeth Conventions, 191
 Darne B, *see* Pannier, 775
 De Backer T, *see* Duprez, 709
 D'Erasmo D, *see* Aliberti, 697
 Dessertenne F, Fabiato A, Coumel P. A new chapter of electrocardiography: the progressive variations in the amplitude of the electrocardiogram (translation), 171
 De Sutter P, *see* Duprez, 709
 Devissaguet M, *see* Ribaut, 1047
 Dhalla NS, Kolar F, Shah KR, Ferrari R. Effects of some L-carnitine derivatives on heart membrane ATPases, 25
 D'Hollander A, *see* Goldstein, 629
 Dieterich HA, *see* Mitrovic, 689
 Di Lisa F, *see* Siliprandi, 11
 Di Paola R, *see* Tamburino, 495
 Dobmeyer DJ, *see* Yamada, 67
 Dumont L, *see* Villière, 997
 Dupont AG, Coupez JM, Jensen P, Coupez-Lopinot R, Schoors DF, Hermanns P, Nicolas M. Twenty-four hour ambulatory blood pressure profile of a new slow-release formulation of diltiazem in mild to moderate hypertension, 701
 Dupont AG, *see* Schoors, 489
 Duprez D, Lefebvre R, De Backer T, De Sutter P, Trouerbach J, Clement DL. Influence of nebivolol on the cardiovascular hemodynamics during postural changes and isometric exercise, 709
 Durr F, *see* Timour, 1043
 Engler R, *see* Mullane, 915
 Epstein M, Loutzenhiser R. Calcium antagonists and the kidney, 659
 Erhardt L, *see* Persson, 589
 Fabiato A, Coumel P. Torsades de pointes, a quarter of a century later: a tribute to Dr. F. Dessertenne, 167
 Fabiato A, *see* Dessertenne, 171
 Fagari R, *see* Lijnen, 741
 Faucon G, *see* Timour, 1043
 Ferrari R. Editor's introduction, 5
 Ferrari R, Ceconi C, Cargnoni A, Pasini E, Boffa GM, Curello S, Visioli O. The effect of propionyl-L-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondria, 57
 Ferrari R, Ceconi C, Curello S, Cargnoni A, Pasini E, Visioli O. The occurrence of oxidative stress during reperfusion in experimental animals and men, 277

- Ferrari R, Pasini E, Condorelli E, Boraso A, Lisciani R, Marzo A, Visiou O. Effect of propionyl-L-carnitine on mechanical function of isolated rabbit heart, 17
- Ferrari R, Visioli O. Stunning: damaging or protective to the myocardium?, 939
- Ferrari R, *see* Dhalla, 25
- Fischer Hansen J. Calcium antagonists and myocardial infarction, 667
- Fitzgerald JD. Introduction to focused section on new developments in beta-blockade, 545
- Fitzgerald JD. The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes, 561
- Fleming JS, Buchanan JO, Yocca FD, Iben LG, Antonaccio MJ. Effect of encaidine, ode, mode and flecainide on ADP/5-HT induced platelet aggregation and in the anesthetized dog coronary artery stenosis-occlusion model of intravascular thrombosis, 763
- Fontaine J, *see* Bohyn, 457
- Forman MB, Valasco CE. Role of adenosine in the treatment of myocardial stunning, 901
- Fouchard M, *see* Pannier, 775
- Fujita T, *see* Yamamoto F, 301
- Fukasawa M, *see* Orita, 727
- Fukunami M, Hashimura K, Ohmori M, Ikeda T, Umemoto K, Kumagai K, Sakai A, Yamada T, Kondoh N, Minamino T, Nagareda T, Kotoh K, Hoki N. Effectiveness of long-term beta-blocker therapy for dilated cardiomyopathy—echocardiographical follow-up, 463
- Gaglione A, *see* Chiddo, 107
- Ganten D, Paul M, Lang RE. The role of neuropeptides in cardiovascular regulation, 119
- Garabedian VG, *see* Pannier, 775
- Garceau D, *see* Villière, 997
- Gersh BJ, Rahimtoola SH. Acute myocardial infarction (book review by L. H. Opie), 1049
- Gersh BJ, *see* Backes, 449
- Giuffrida G, *see* Tamburino, 495
- Glocke MH, *see* Maetzel, 647
- Goldstein M, Vincent J-L, Le Clerc J-L, d'Hollander A, Melot C, Kahn RJ. Hemodynamic evaluation of bisoprolol after coronary artery surgery in patients with altered left ventricular function, 629
- Griebel A, *see* Maetzel, 647
- Grimaldi N, *see* Chiddo, 107
- Guy S, *see* Silke, 681
- Gwathmey JK, *see* Hajjar, 961
- Hajjar RJ, Gwathmey JK. Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical view, 961
- Hampton JR. The treatment of hypertension: new lamps for old?, 983
- Harasawa Y, *see* Schipke, 481
- Harpey C, *see* Timour, 1043
- Hartley CJ, *see* Bolli, 877
- Haruno A, *see* Hashimoto, 805
- Hasegawa J, *see* Noguchi, 987
- Hashimoto K, Haruno A, Matsuzaki T, Sugiyama A, Akiyama K. Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness?, 805
- Hashimoto K, Kinoshita M, Ohbayashi Y. Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs, 131
- Hashimura K, *see* Fukunami, 463
- Hatori N, Sjöquist P-O, Regårdh C, Rydén L. Pharmacokinetic analysis of coronary sinus retroinfusion in pigs ischemic myocardial concentrations in the left circumflex coronary arterial area using metoprolol as a tracer, 1005
- Hearse DJ. Reperfusion-induced injury: a possible role for oxidant stress and its manipulation, 225
- Hearse DJ. Reperfusion injury: progress and problems, 313
- Hearse DJ. Stunning: a radical re-view, 853
- Heijnis JB, Coronel R, Van Zwieten PA. The effects of calcium antagonists on extracellular potassium accumulation during global ischaemia in isolated perfused rat hearts, 1035
- Herbaczyńska-Cedro K, *see* Ceremużyński, 643
- Hermanns P, *see* Dupont, 701
- Herrmann G, *see* Amende, 497
- Hiejima K, *see* Hirao, 819
- Hirao K, Okishige K, Suzuki F, Hiejima K. Combination therapy with aprindine and verapamil for paroxysmal supraventricular tachycardia as assessed by transesophageal atrial pacing, 819
- Hiraoka M, Nitta J, Sunami A, Sawanobori T. Combined effects of different class I antiarrhythmic agents on maximum rate of depolarization (V_{max}) of action potentials in guinea-pig papillary muscles, 791
- Hiraoka M, *see* Sakurada, 835
- Hirooka S, *see* Orita, 727
- Hisatome I, *see* Noguchi, 987
- Hodsmen GP, *see* Howes, 147
- Hoensch HP, *see* Wensing, 733
- Hoffmeister HM, Seipel L. Hemodynamic effects of the D- and L-isomers of sotalol on normal myocardium, 1027
- Höfling B, *see* Von Polnitz, 153
- Hohnloser S, *see* Zehender, 515
- Hoki N, *see* Fukunami, 463
- Hood WP Jr., *see* Amende, 497
- Howes LG, Hodsmen GP, Rowe PR, Johnston CI. Comparative effects of angiotensin converting enzyme inhibition (perindopril) or diuretic therapy on cardiac hypertrophy and sympathetic activity following myocardial infarction in rats, 147
- Hülsman WC. Biochemical profile of propionyl-L-carnitine, 7
- Hütting W, *see* Mitrovic, 967
- Huyghens L, *see* Schoors, 489
- Iben LG, *see* Fleming, 763
- Ichikawa H, *see* Yamamoto F, 301
- Iizuka K, *see* Takahashi, 1021
- Ikeda T, *see* Fukunami, 463
- Imai S, *see* Ishibashi, 635
- Ingold KU, *see* Mickle, 309
- Ioakimides C, *see* Caralis, 155
- Ishibashi T, Tatebe S, Mitomi A, Tanaka M, Imai S. Hemodynamic effects of benazepril, an angiotensin-converting enzyme inhibitor, as studied in conscious normotensive dogs, 635
- Jennings RB, Murry CE, Reimer KA. Pre-conditioning myocardium with ischemia, 933
- Jensen P, *see* Dupont, 701
- Johnston CI, *see* Howes, 147
- Just H, *see* Zehender, 515
- Kagami A, *see* Mochizuki, 269
- Kahn RJ, *see* Goldstein, 629
- Kaiser FC, *see* Knillans, 139
- Kanda T, *see* Yokoyama, 471
- Kanter EM, *see* Yamada, 67
- Kaplan N. Clinical hypertension (5th edition), 164
- Kaplan NM. New approaches for the treatment of hypertension, 973
- Kaski JC, Araujo L, Maseri A. Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease, 991
- Kaumann AJ. Some aspects of heart beta-adrenoceptor function, 549
- Kawaguchi H, *see* Makiguchi, 753
- Kawaguchi H, *see* Takahashi, 1021
- Kawamura T, *see* Toyama, 801
- Keren A, *see* Tzivoni, 505
- Keren A, Tzivoni D. Torsades de pointes: prevention and therapy, 509
- Kinoshita M, *see* Hashimoto, 131
- Kloner RA, *see* Przyklenk, 947

- Klos J, *see* Ceremuzyński, 643
- Knilians TK, Varró A, Nánási PP, Murray RJ, Kaiser FC, Lathrop DA. Electrophysiologic effects of FPL 13210 on canine purkinje fiber action potential duration and V_{max} : comparison to disopyramide, 139
- Kodama I, *see* Toyama, 801
- Kolar F, *see* Dhalla, 25
- Kondoh N, *see* Fukunami, 463
- Kordenat K, *see* Leasure, 85
- Kosakai Y, *see* Yamamoto F, 301
- Kotake H, *see* Noguchi, 987
- Kotoh K, *see* Fukunami, 463
- Kumagai K, *see* Fukunami, 463
- Kuraoka S, *see* Orita, 727
- Kyriakides Z, *see* Caralis, 155
- Lang RE, *see* Ganten, 119
- Lathrop DA, *see* Knilians, 139
- Leasure JE, Kordenat K. Effect of propionyl-L-carnitine on experimental myocardial infarction in dogs, 85
- Le Clerc J-L, *see* Goldstein, 629
- Lefebvre M, *see* Villière, 997
- Lefebvre R, *see* Duprez, 709
- Lerch R. Oxidative metabolism in reper-fused myocardium, 953
- Lichtlen PR, *see* Amende, 497
- Liedtke AJ, *see* Bolukoglu, 37
- Lijnen P, Fagard R, Staessen J, Amery A. Hormonal effect of the diuretic xipamide in healthy men, 741
- Lisciani R, *see* Ferrari, 17
- Littler WA, *see* West, 747
- Liu E, *see* Cheitlin, 719
- Locuratolo N, *see* Chiddo, 107
- Lorenz H-M, *see* Von Polnitz, 153
- Loutzenheiser R, *see* Epstein, 659
- Lund-Johansen P, Omvik P. Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha-blockers and different types of beta-blockers with and without vasodilating effect, 605
- McArdavey D, Vermeulen R, Robertson JIS. Newer beta-blockers and the treatment of hypertension, 577
- McDonough KH, *see* Ross-Ascuitto, 1011
- Madonna O, *see* Pannier, 775
- Maetzel F-K, Teufel WE, Griebel A, Glocke MH. Double-blind, randomized comparative study of the anti-hypertensive effect of nicardipine slow-release and nifedipine slow-release in hypertensive patients with coronary heart disease, 647
- Makiguchi M, Kawaguchi H, Tamura M, Yasuda H. Effect of palmitic acid and fatty acid binding protein on ventricular fibrillation threshold in the perfused rat heart, 753
- Marban E. Pathogenetic role for calcium in stunning, 891
- Maruyama T, *see* Sunamori, 297
- Marzo A, *see* Ferrari, 17
- Maseri A, *see* Kaski, 991
- Mashiba H, *see* Noguchi, 987
- Matsuoka S, *see* Noguchi, 987
- Matsuzaki T, *see* Hashimoto, 805
- Melot C, *see* Goldstein, 629
- Menabo R, *see* Siliprandi, 11
- Mickle DAG, Weisel RD, Burton GW, Ingold KU. Effect of orally administered alpha-tocopheryl acetate on human myocardial alpha-tocopherol levels, 309
- Mikawa T, *see* Tanabe, 677
- Millar RN Scott. Torsades de pointes: arrhythmia, syndrome or chimera?, 201
- Minamino T, *see* Fukunami, 463
- Mitomi A, *see* Ishibashi, 635
- Mitrovic V, Patyna W, Hütting W, Schlepper M. Hemodynamic and neuro-humoral effects of mononidine in patients with essential hypertension, 967
- Mitrovic V, Petrovic O, Bahavar H, Neuzner J, Dieterich HA, Schlepper M. Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease: relation to plasma concentration, 689
- Mochizuki S, Okumura M, Tanaka F, Sato T, Kagami A, Tada N, Nagano M. Ischemia-reperfusion arrhythmias and lipids: effect of human high- and low-density lipoproteins on reperfusion arrhythmias, 269
- Modin G, *see* Cheitlin, 719
- Mönig H, *see* Wensing, 733
- Mori H, *see* Singh, 1045
- Motomiya T, *see* Sakurada, 835
- Mullane K, Engler R. Proclivity of activated neutrophils to cause post-ischemic cardiac dysfunction: participation in stunning?, 915
- Murakami E, *see* Takekoshi, 289
- Murata K, *see* Yokoyama, 471
- Murayama M, *see* Tanabe, 677
- Murray RJ, *see* Knilians, 139
- Murry CE, *see* Jennings, 933
- Musci S, *see* Chiddo, 107
- Nadeau R, *see* Ribaut, 1047
- Nagano M, *see* Mochizuki, 269
- Nagareda T, *see* Fukunami, 463
- Nánási PP, *see* Knilians, 139
- Napolitano C, *see* Priori, 203
- Nawada T, *see* Noguchi, 987
- Nellis SH, *see* Bolukoglu, 37
- Neuzner J, *see* Mitrovic, 689
- Nicolas M, *see* Dupont, 701
- Nitta J, *see* Hiraoka, 791
- Noda K, *see* Tanabe, 677
- Noguchi N, Hasegawa J, Omodani H, Nawada T, Matsuoka S, Hisatome I, Kotake H, Mashiba H. Effect of urapidil on the action potentials in the guinea-pig ventricular myocardium, 987
- Norbiato G, *see* Bevilacqua, 31
- Oddo CM, *see* Aliberti, 697
- Ohbayashi Y, *see* Hashimoto, 131
- Ohkubo S, *see* Takekoshi, 289
- Ohmori M, *see* Fukunami, 463
- Ohnhaus EE, *see* Wensing, 733
- Okishige K, *see* Hirao, 819
- Okumura M, *see* Mochizuki, 269
- Omodani H, *see* Noguchi, 987
- Omvik P, *see* Lund-Johansen, 605
- Opie LH. Acute myocardial infarction (book review), 1049
- Opie LH. Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias, 671
- Opie LH. Clinical electrocardiography (book review), 1049
- Opie LH. Post ischemic stunning: the case for calcium as the ultimate culprit, 895
- Opie LH. Reperfusion injury: fad, fashion or fact?, 223
- Opie LH. Role of calcium and other ions in reperfusion injury, 237
- Orita H, Shimanuki T, Fukasawa M, Abe H, Kuraoka S, Hirooka S, Washio M. Accelerated myocardial metabolic and functional recovery with terminal nicorandil-Mg cardioplegia in heart transplantation, 727
- Pannier BE, Garabedian VG, Madonna O, Fouchard M, Darne B, Safar ME. Lisinopril versus atenolol: decrease in systolic versus diastolic blood pressure with converting enzyme inhibition, 775
- Pasini E, *see* Ferrari, 17
- Pasini E, *see* Ferrari, 57
- Pasini E, *see* Ferrari, 277
- Patyna W, *see* Mitrovic, 967
- Paul M, *see* Ganten, 119
- Paulson D, *see* Shug, 77
- Persson H, Erhardt L. Beta-receptor antagonists in the treatment of heart failure, 589
- Petrovic O, *see* Mitrovic, 689
- Priori SG, Napolitano C, Schwartz PJ. Electrophysiologic mechanisms involved in the development of torsades de pointes, 203
- Priori SG, *see* Yamada, 67
- Przyklenk K, Kloner RA. Calcium antag-

- onists and stunned myocardium: importance for clinicians?, 947
- Rabinovitz RS, *see* Bolli, 877
- Ramage D, *see* Ross-Ascuito, 1011
- Regårdh C, *see* Hatori, 1005
- Regitz V, *see* Shug, 77
- Reimer KA, *see* Jennings, 933
- Reynaert H, *see* Schoors, 489
- Ribuot C, Nadeau R, Yamaguchi N, Devissaguet M, Scalbert E, Rochette L. Lack of effect of perindoprilat, an angiotensin-I converting enzyme inhibitor, during coronary artery occlusion and reperfusion in the anesthetized dog, 1047
- Rizzon P, *see* Chiddo, 107
- Robertson JIS, *see* McAreavey, 577
- Rochette L, *see* Ribuot, 1047
- Ross-Ascuito NT, Ascuito RJ, Ramage D, McDonough KH. The effects of milrinone in the neonatal pig heart, 1011
- Rowe PR, *see* Howes, 147
- Rowlands, DJ. Clinical electrocardiography (book review by L. H. Opie), 1049
- Russo G, *see* Tamburino, 495
- Rydén L, *see* Hatori, 1005
- Safer ME, *see* Pannier, 775
- Sakai A, *see* Fukunami, 463
- Sakamoto T, *see* Sunamori, 297
- Sakurada H, Motomiya T, Hiraoka M. Efficacy of disopyramide and mexiletine used alone or in combination in the treatment of ventricular premature beats, 835
- Sato T, *see* Mochizuki, 269
- Sawanobori T, *see* Hiraoka, 791
- Scalbert E, *see* Ribuot, 1047
- Schaper W. Molecular mechanisms in "stunned" myocardium, 925
- Scheffer MA, *see* Van Hinsbergh, 97
- Schena F, *see* Cevese, 45
- Schipke JD, Harasawa Y, Sugiura S, Alexander J, Burkhoff D. Effect of a bradycardic agent on the isolated blood-perfused canine heart, 481
- Schlepper M, *see* Mitrovic, 689
- Schlepper M, *see* Mitrovic, 967
- Schoors DF, Reynaert H, Huyghens L, Vanhaelst L, Dupont AG. Protective effects of felodipine and verapamil against imipramine-induced lethal cardiac conduction disturbances in the anaesthetized rat, 489
- Schoors DF, *see* Dupont, 701
- Schwartz PJ, *see* Priori, 203
- Seipel L, *see* Hoffmeister, 1027
- Shah KR, *see* Dhalla, 25
- Shimanuki T, *see* Orita, 727
- Shug A, Paulson D, Subramanian R, Regitz V. Protective effects of propionyl-L-carnitine during ischemia and reperfusion, 77
- Siliprandi N, Di Lisa F, Menabo R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism, 11
- Silke B, Verma SP, Guy S. Hemodynamic interactions of a new beta-blocker, celiprolol, with nifedipine in angina pectoris, 681
- Simon R, *see* Amende, 497
- Singh RB. Non-pharmacologic methods for lowering blood pressure, 157
- Singh RB, Mori H. Can nutritional factors enhance hyperinsulinemia leading to coronary heart disease?, 1045
- Sjöquist P-O, *see* Hatori, 1005
- Smith HJ. Potential impact of antioxidants administered unknowingly to experimental animals in laboratory diets, 159
- Staessen J, *see* Lijnen, 741
- Stallard TJ, *see* West, 747
- Stern S, *see* Tzivoni, 505
- Subramanian R, *see* Shug, 77
- Sugai J, *see* Tanabe, 677
- Sugiura S, *see* Schipke, 481
- Sugiyama A, *see* Hashimoto, 805
- Sultan I, *see* Sunamori, 297
- Sunami A, *see* Hiraoka, 791
- Sunamori M, Tanaka H, Maruyama T, Sultan I, Sakamoto T, Suzuki A. Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization, 297
- Suzuki A, *see* Sunamori, 297
- Suzuki F, *see* Hirao, 819
- Suzuki T, *see* Yokoyama, 471
- Swales JD. The level at which blood pressure should be treated, 979
- Swynghedauw B. Cardiac hypertrophy and failure, 163
- Tada N, *see* Mochizuki, 269
- Takahashi A, *see* Yamamoto F, 301
- Takahashi H, Kawaguchi H, Iizuka K, Yasuda H. The leakage of fatty acid binding protein from cultured myocardial cells during hypoxia, 1021
- Takekoshi N, Murakami E, Ohkubo S. Effects of some radical scavengers on reperfusion-induced arrhythmias in the canine heart, 289
- Tamburino C, Russo G, Di Paola R, Giuffrida G. Pulmonary edema during cardiac catheterization successfully treated with bolus administration of nicardipine, 495
- Tamura M, *see* Makiguchi, 753
- Tanabe K, Noda K, Mikawa T, Murayama M, Sugai J. Magnesium content of erythrocytes in patients with vasospastic angina, 677
- Tanabe T. Combination antiarrhythmic treatment among class Ia, Ib, and II agents for ventricular arrhythmias, 827
- Tanaka F, *see* Mochizuki, 269
- Tanaka H, *see* Sunamori, 297
- Tanaka K, *see* Yamamoto F, 301
- Tanaka M, *see* Ishibashi, 635
- Tatebe S, *see* Ishibashi, 635
- Teufel WE, *see* Maetzel, 647
- Thulesius O, *see* Yousif, 769
- Timour Q, Harpey C, Durr F, Faucon G. Is the antianginal action of trimetazidine independent of hemodynamic changes?, 1043
- Toyama J, Kawamura T, Kodama I. Effects of combined use of class I antiarrhythmic agents on V_{max} of guinea-pig ventricular muscles, 801
- Troito G, *see* Chiddo, 107
- Trouerbach J, *see* Duprez, 709
- Tzivoni D, Keren A, Banai S, Stern S. Terminology of torsades de pointes, 505
- Tzivoni D, *see* Keren, 509
- Umemoto K, *see* Fukunami, 463
- Vago T, *see* Bevilacqua, 31
- Vanhaelst L, *see* Schoors, 489
- Van Hinsbergh VWM, Scheffer MA. Effect of propionyl-L-carnitine on human endothelial cells, 97
- Van Zweiten PA, *see* Hejnis, 1035
- Varró A, *see* Knillans, 139
- Vecci E, *see* Aliberti, 697
- Velasco CE, *see* Forman, 901
- Verma SP, *see* Silke, 681
- Vermeulen R, *see* McAreavey, 577
- Villière V, Dumont L, Lefebvre M, Garceau D, Chartrand C, Caillé G. Relationship between the cardiovascular effects and both plasma and myocardial levels of clentiazem, a new benzothiazepine calcium antagonist, in anesthetized dogs, 997
- Vincent J-L, *see* Goldstein, 629
- Visioli O, *see* Ferrari, 57
- Visioli O, *see* Ferrari, 277
- Visioli O, *see* Ferrari, 939
- Visioli O, *see* Ferrari, 17
- Von Polnitz A, Lorenz H-M, Höfling B. Ambulatory blood pressure monitoring for the evaluation of once-daily ACE inhibition: a comparison study of captopril and enalapril combined with hydrochlorothiazide, 153
- Washio M, *see* Orita, 727
- Weisel RD, *see* Mickle, 309
- Wensing G, Mönig H, Ohnhaus EE, Hoensch HP. Pharmacokinetics of encainide in patients with cirrhosis, 733

- Wenzlaff P, *see* Amende, 497
- West JNW, Champion de Crespigny PC, Stallard TJ, Littler WA. Effects of the angiotensin converting enzyme inhibitor, benazepril, on the sino-aortic baroreceptor heart rate reflex, 747
- Yagihara T, *see* Yamamoto F, 301
- Yamada KA, Dobmeyer DJ, Kanter EM, Priori SG, Corr PB. Delineation of the influence of propionyl-L-carnitine on the accumulation of long chain acylcarnitines and electrophysiologic derangements evoked by hypoxia in canine myocardium, 67
- Yamada T, *see* Fukunami, 463
- Yamaguchi N, *see* Ribuot, 1047
- Yamamoto F, Yamamoto H, Yoshida S, Ichikawa H, Takahashi A, Tanaka K, Kosakai Y, Yagihara T, Fujita T. The effects of several pharmacologic agents upon postischemic recovery, 301
- Yamamoto H, *see* Yamamoto F, 301
- Yasuda H, *see* Makiguchi, 753
- Yasuda H, *see* Takahashi, 1021
- Yocca FD, *see* Fleming, 763
- Yokoyama T, Kanda T, Suzuki T, Murata K. Preventive effects of OK432 on murine acute myocarditis due to encephalomyocarditis virus, 471
- Yoshida S, *see* Yamamoto F, 301
- Yousif MHF, Thulesius O. Effect of mol-sidomine metabolite Sin-1 on coronary arteries and peripheral vessels of sheep with special reference to tolerance and endothelium, 769
- Zamorano B. Subcellular localization of prostaglandin-E2 in rat heart tissue, 655
- Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards, 515

Subject Index

- Acebutolol
atrial fibrillation therapy, 619
beta-blocker studies in heart failure, 591
as beta-blocker therapy for dilated cardiomyopathy, 467
ischemic heart disease studies, 594
left ventricular hypertrophy, 581
no downregulation in congestive heart failure, 594
partial agonist activity, 567
receptor properties, 597
subclassification in pharmacologic properties, 564
- Aceplus, for hypertension, 975
- Acetate uptake, related to oxygen uptake in myocardial stunning, 928
- n-(2-Acetoxyethyl) nicotinamide (SG-209), 137
- Acetylcarnitine, effect beneficial on ischemic hearts, 25, 27-29
- Acetyl-L-carnitine
decrease of cytoplasmic calcium level in endothelial cells, 97
effect on heart mitochondrial superoxide formation, 81
effect on human endothelial cells, 100, 103
improvement of cardiac output in isolated ischemic rat hearts, 77, 79-82
vs. propionyl-L-carnitine for global ischemia, 31
- Acidosis*
pharmacologic treatment of atrial fibrillation, 617
plasmalemma protected by propionyl-L-carnitine, 7
- Action potential
antiarrhythmic drugs and their effect on canine triggered arrhythmias, 813, 814, 815
maximum rate of depolarization affected by class I antiarrhythmic agents, 791-799
prolonged by oxidant stress, 864
slow, urapidil electrophysiological effects, 987-990
- Action potential duration (APD), disopyramide vs. FPL 13210 electrophysiologic effects, 139-146
- Acute myocardial infarction (AMI)
beta-receptor antagonists in heart failure, 593-594, 595, 599
book review (B. J. Gersh and S. H. Rahimtoola), 1049-1050
serotonin and platelet aggregation, 763, 767
tiapamil with propionyl-L-carnitine to limit infarct size, 85-86
- Acute myocardial infarction with early reperfusion, 942
and myocardial stunning, 879, 882, 887
- Acylcarnitines
involving propionyl-L-carnitine in stabilizing action, 5
stabilizing action upon biomembranes, 7
- Acylcarnitine/carnitine ratios, 13
- Adalat, for hypertension, 975
- Additive and synergistic inhibition, flecainide and mexiletine combination therapy on guinea-pig ventricular muscles, 803
- Adenine nucleotide translocase, action improved by carnitine, 42
- Adenosine (ADO)
ischemic preconditioning, 934, 936-937
role in myocardial stunning treatment, 901-906
to protect against myocardial stunning, 910, 912, 919
- Adenosine diphosphate (ADP)
ischemic preconditioning, 936
role in myocardial stunning treatment, 902
- Adenosine monophosphate (AMP)
role in myocardial stunning treatment, 902
- Adenosine triphosphate (ATP)
breakdown caused by propionate, 5
depletion characteristic of myocardial stunning, 949
effect of propionate, 13
and hibernating myocardium, 940-941
ischemic preconditioning, 933-938
myocardial stunning and molecular mechanisms, 927
potassium channel regulation in rat hearts, 1040
production at mitochondrial level without oxygen consumption, 5
production increased by propionyl-L-carnitine, 5
propionyl-L-carnitine depletion of heart tissue stores, 57, 58, 62-63
role in treatment of myocardial stunning, 901-906
- Adenosine triphosphatase (ATP-ase), propionyl-L-carnitine having no major effect on heart membrane, 22

- Adenylate cyclase, stimulation by CGRP, 123-124
- Adenylyl cyclase, coupled to beta adrenoceptors and beta₂ adrenoceptors, 549-553, 555-557
- Adrenaline-induced arrhythmias, antiarrhythmic drug effects, 805-807, 809-816
- Adrenergic receptor blockers, vs. beta blockers, 605-614
- Aequorin, injections used to measure calcium transients in ferret hearts, 239
- AFD-19 (antiarrhythmic drug), effect on triggered arrhythmias in dogs, 809, 813
- After depolarizations, calcium-dependent, induced, 671, 674
- AHR 10718 (antiarrhythmic drug), effect on triggered arrhythmias in dogs, 810, 812-813, 814
- Ajmalina, atrial fibrillation therapy, 621, 622
- Ajmaline, single-drug therapy in Japan for VPB's, 838
- Alcoholism, torsades de pointes treatment affected, 512
- Aldactazide, for hypertension, 975
- Aldactone, for hypertension, 975
- Aldosterone, nisoldipine effect on stress-induced activation in conscious pig, 643-646
- Allopurinol
improved functional recovery of the stunned myocardium, 251, 252
myocardial infarct size affected, 263
and myocardial stunning, 857, 887, 909
protective effect to myocardium against reperfusion damage, 279
to counteract reperfusion arrhythmias after ischemia, 293
to reduce incidence of reperfusion-induced ventricular fibrillation and no-reflow phenomenon, 227, 230, 232
- Alpha-adrenergic receptor blockers, blood pressure reduction, 605-609, 612
- Alpha-adrenergic receptors
long-chain acylcarnitines and propionylcarnitine in dogs, 68, 73-74
not inhibiting fatty acid binding protein to prevent cell death, 1021, 1023, 1025
- Alpha blockers
effect on blood pressure with beta blockers, 569
electrophysiological and antiarrhythmic effects, 987-990
and hypertension, 977
- Alpha-phenyl *N*-tert-butyl nitron (PBN)
effect on myocardial stunning after coronary occlusion, 252-259
spin trap used to determine free radicals, 858-859, 860, 909
- Alpha-tocopherol
alpha-tocopheryl acetate effect when orally administered, 309-312
depleted during myocardial ischemia, 279
improving post-ischemic contractile function recovery, 856
- Alprenolol, 556
heart failure studies, 590
hemodynamic effects, 606
intrinsic sympathomimetic activity, 566, 567
receptor properties, 597
- Amantadine, QT prolongation and proarrhythmic risk, 524
- Amatadine, antiarrhythmic efficacy and proarrhythmic risk, 524
- Ambulatory blood pressure monitoring, captopril and enalapril with hydrochlorothiazide compared in once-daily ACE inhibition evaluation, 153-154
- diltiazem slow-release profile for hypertension, 701-706
to establish blood pressure profiles for nicardipine slow-release and nifedipine slow-release, 647-649, 651-653
- Amflutizole
myocardial infarct size affected, 263
and myocardial stunning, 857
- Amiloride
hemodynamic effects when patient taking digoxin for chronic heart failure, 719-724
pretreatment decreasing calcium uptake in myocardial stunning, 895
to inhibit sodium-calcium exchange in reperfusion injury, 242-243
- 5-Amino-4-imidazolcarboxamide riboside (AICAR), 905
- Aminophylline, QT prolongation, 524
- Amiodarone
antiarrhythmic efficacy and proarrhythmic risk, 519, 522, 524
inducing torsades de pointes, 505, 506, 509, 511
preventing atrial fibrillation relapses in spite of side effects, 617, 620-624
- Amitriptyline, QT prolongation and proarrhythmic risk, 523
- Amlodipine, improving systolic contraction, 947
- Amosulalol, 570
characteristics, 579
comparative beta blocker classification, 564
technico-commercial status, 546
- Ampicillin, QT prolongation and proarrhythmic risk, 524
- Amrinone
effect on triggered arrhythmias in dogs, 814
negative inotropic effect, 1018
vs. digitalis, 962
- AN-132 (antiarrhythmic drug), effect on triggered arrhythmias in dogs, 810, 812-813, 814, 815
- Anaerobic glycolysis, energy source in severe ischemia, 935-936
- Anagrelide, 768
- Anaplerotic function, 5
- Anesthesia with halothane and cyclopropane, beta blocker therapy for AF, 619
- Angina pectoris
beta blockers, 561
bisoprolol, 629
celiprolol hemodynamic interactions with nifedipine, 681-686
enoximone hemodynamic and antiischemic effects, 689-695
increase of Thromboxane A₂, 273
molsidomine metabolite SIN-1 effect, 769
newer beta blockers not reviewed, 547
nicardipine therapy, 653
oxyfedrine effect on regional blood flow, 991-995
trimetazidine and hemodynamic changes, 1043-1044
with hypertension and beta blocker therapy, 607
- Angioplasty, 942, 943
- Angiotensin
biochemistry, 120
distribution, 120
role in cardiovascular regulation, 119-121
- Angiotensin converting enzyme inhibitors
benazepril effect on sino-aortic baroreceptor heart rate reflex, 747-750
captopril and enalapril with hydrochlorothiazide evaluated, 153-154
as coronary artery disease therapy for elderly, 450
cost, 980
for hypertension, 975, 977, 979, 984
perindoprilat effect during coronary artery occlusion and reperfusion in dogs, 1047-1048
to ameliorate reperfusion arrhythmias, 244
to increase cellular cytosolic calcium concentrations, 244
- Angiotensin converting enzyme inhibition (ACEI) therapy
comparative effects with diuretics on cardiac hypertrophy and sympathetic activity following myocardial infarction in rats, 147-151
- Antiarrhythmic agents
aprimidine with verapamil for tachycardia, 819-824
and atrial fibrillation, 617-624
canine ventricular arrhythmia models' electrophysiological characteristics, 805-816
combination therapy for paroxysmal

- supraventricular tachycardia assessed by transeophageal atrial pacing, 819-824
- combination therapy for ventricular arrhythmias, 827-833
- electrophysiologic effects on canine Purkinje fiber action potential duration and V_{max} , 139-146
- FPL 13210 reducing incidence greater than disopyramide, 139
- QT-interval prolongation, 517, 519-524 and reperfusion (151-156) 365-366, (P363-P377) 401-403
- Antibiotics, QT prolongation observed, 524
- Antibodies, monoclonal, to inhibit neurophil activity, 911, 916-917, 919, 920
- Anticoagulants, and antiplatelet agents, (461-466) 413-414
- Antihypertensive therapy, 973-981
- Anti-ischemic drugs, (P34-P48) 333-335 and myocardial ischemia, (P348-P362) 397-399
- Antioxidants
- exogenous sources administered to laboratory animals, 159
 - and myocardial stunning, 856, 858-860, 885, 887, 942-943
- Antiplatelet agents, 768
- and anticoagulants, (461-466) 413-414
 - and thrombolysis, (13-18) 327-328, (P178-P192) 373-375
- Antipyrine, elimination assessed to evaluate encaidine pharmacokinetics in cirrhosis patients, 733-738
- Antiserotonin, encaidine activity in platelet aggregation and canine intravascular thrombosis, 766-767
- Antithrombotic therapy, acute myocardial infarction, 1050
- Aortocoronary bypass grafting
- alpha-tocopheryl acetate effect, 309-312
 - and myocardial stunning, 881
- Aprindine
- causing QT-interval prolongation and torsades de pointes, 520
 - effect on triggered arrhythmias in dogs, 813, 815
 - QT prolongation, 524
 - single-drug therapy in Japan for VPB's, 838
 - with verapamil for tachycardia, 819-824
- Arrotinolol, 570
- characteristics, 579
 - comparative beta blocker classification, 564
 - technico-commercial status, 546
- Arrhythmias
- calcium excess oscillations as contribution to reperfusion injury, 237, 240-244
 - classification schemes, 191-199
 - diuretics effects, 147
 - electrocardiographic description, 171-190
 - incidence reduced by ACEI therapy, 147, 151
 - perindoprilat effect during coronary artery occlusion and reperfusion in dogs, 1047-1048
 - reperfusion-induced, 227-229, 232
 - reperfusion-induced and myocardial stunning, 854, 855, 857, 858
 - tachycardias, torsades de pointes and early afterdepolarization, 531-536
 - torsades de pointes mechanism of perpetuation, 167-168
- Arrhythmogenesis, oxidant stress role during ischemia and reperfusion, 227-229
- Arsenic, QT prolongation and proarrhythmic risk, 524
- Arterial compliance
- beta blocker therapy, 581
 - increased by IV propionyl-L-carnitine, 107-111
 - increase from lisinopril and atenolol, while also decreasing systolic blood pressure, 775, 781
- Ascorbate
- as antioxidant defense mechanism, 231, 232
 - depleted during myocardial ischemia, 279
- Aspirin, 768
- secondary postinfarct prevention, 1050
- Astemizol, QT prolongation and proarrhythmic risk, 524
- Asthma
- and beta blocker therapy, 569, 572, 582, 583
 - celiprolol or bisoprolol treatment under close supervision, 571
- Atenolol, 565
- blood pressure effect, 568, 606
 - cardioselective, 578
 - causing increase in cardiac β_2 adrenoceptors, 545
 - cold peripheries and caudication, 568
 - effect on diastolic function, 595
 - effect on triggered arrhythmias in dogs, 814
 - efficacy, 580
 - for hypertension, 975
 - heart beta-adrenoceptor function, 554, 555
 - ICI 118551 added, 566
 - ischemic heart disease studies, 593
 - left ventricular hypertrophy, 581
 - matrix of factors for evaluation, 572
 - metabolic effects, 571
 - plasma lipoprotein profiles altered, 569
 - receptor properties, 597
 - respiratory function, 582
 - vs. lisinopril for mild to moderate essential hypertension, 775-781
 - vs. nebivolol, 570
- Atherogenesis, (119-124) 357-358
- plasma-cell interactions, (P106-P118) 353-355
- Atherosclerosis
- beta-receptor antagonist effects, 596
 - diet and hyperinsulinemia, 1045
 - lipid metabolism abnormality effect, 269
- Atrial fibrillation (AF)
- bisoprolol after coronary artery surgery, 631
 - drug prophylaxis, 623-624
 - pharmacologic treatment, 617-624
 - sinus rhythm restoration, 620-623
- Atrial natriuretic peptide (ANP), xipamide effect on plasma alpha-ANP concentrations in healthy men, 741-745
- Atrioventricular block, beta blocker therapy, 572
- Atrioventricular nodal reentrant tachycardia, aprindine with verapamil therapy, 824
- Atropine, therapy for torsades de pointes, 506, 511
- Azathioprine, immunosuppressive therapy for viral myocarditis, 477
- Balloon dilatation, as coronary artery disease treatment, 449, 453
- Barium, QT prolongation and proarrhythmic risk, 524
- Bay-K-8644, and myocardial stunning, 896
- Benazepril
- effect on sino-aortic baroreceptor heart rate reflex, 747-750
 - hemodynamic effects in conscious normotensive dogs, 635-641
- Benzamil chloride, effect on DADs and EADs, 210
- Bepidil
- antiarrhythmic tendency and proarrhythmic risk, 523
 - effect on triggered arrhythmias in dogs, 810, 814
- Beta-adrenergic blockers, *see also* Beta blockers
- effectiveness as therapy for dilated cardiomyopathy, 463-467
 - to inhibit calcium in reperfusion injury, 241
- Beta adrenoceptors
- heart beta adrenoceptor function, 549-557
 - inhibiting fatty acid binding protein to prevent cell death, 1021, 1023, 1024, 1025
- Beta₁ adrenoceptors, heart beat increased along with other functions, 549-557
- Beta₂ adrenoceptors, heart beat in-

- creased along with other functions, 549-557
- Beta₂ adrenoceptors, heart beat increased along with other functions, 549-557
- Beta blockers, *see also* Beta-adrenergic blockers
- acute myocardial infarction (book review), 1050
 - alpha adrenoceptors, 570
 - antiarrhythmic efficacy and proarrhythmic risk, 519, 520, 521
 - antihypertensive, 580
 - antihypertensive effects, 561
 - assessment criteria, 562-563
 - atrial fibrillation therapy, 621, 622, 624
 - central and peripheral hemodynamics, 567-571
 - chronic vasodilation maintained by added alpha₁ blockade, 605
 - clinical outcome effect on applied pharmacology, 561-573
 - congestive heart failure beneficial effects, 594
 - as coronary artery disease therapy for elderly, 450
 - depression of cardiac pumping during exercise with angina pectoris, 681
 - effect on triggered arrhythmias in dogs, 810
 - for hibernating myocardium, 942, 943
 - for hypertension, 577-583, 974-975, 977, 983, 984
 - for ventricular arrhythmias, 827-828, 833
 - global assessment, 572-573
 - hemodynamic evaluation after CABG with altered left ventricular function, 629-632
 - matrix of factors for evaluation, 572
 - metabolic effects, 571-572
 - new agents and clinical outcomes, 561-573
 - nonadrenoceptor vasodilators, 570
 - oxyfedrine, 991-995
 - partial agonist activity (PAA): intrinsic sympathomimetic activity (ISA), 566-571
 - peripheral vascular resistance increased, 569
 - plasma lipoprotein profiles altered, 569
 - respiratory effects, 569
 - secondary postinfarct prevention, 1050
 - selectivity and subclassifications in pharmacologic properties, 563-566
 - sotalol isomers' hemodynamic effects on myocardium, 1027-1032
 - technico-commercial status of newer agents, 546
 - vasodilator tolerance, 571
 - vasodilatory, 569
 - vs. adrenergic receptor blockers, 605-614
 - vs. calcium antagonists in preventing sudden death, 673-674
- Beta-receptor antagonists, heart failure treatment, 589-601
- Betaxolol
- ambulatory blood pressure monitoring results consistent, 705
 - characteristics, 579
 - comparative beta blocker classification, 564
 - effect on blood lipids, 582
 - effect on triggered arrhythmias in dogs, 810, 814
 - efficacy, 580
 - pharmacokinetics, 582
 - receptor properties, characteristics, and effects, 597, 599
 - technico-commercial status, 546
- Bevantolol
- cardiac function, 580
 - characteristics, 579
 - comparative beta blocker classification, 564
 - effect on blood lipids, 582
 - efficacy, 580
 - resistance arterial changes, 581
 - respiratory function, 582
 - technico-commercial status, 546
- Bisoprolol, 565
- angina pectoris, 629
 - beta blocker therapy in the elderly, 582
 - cardiac function, 580
 - characteristics, 578, 579
 - clinical evaluation programs, 573
 - comparative beta blocker classification, 564
 - effect on blood lipids, 581, 582
 - efficacy, 580
 - hemodynamic evaluation after coronary artery surgery with altered left ventricular function, 629-632
 - negative chronotropic effect, 600
 - pharmacokinetics, 582
 - receptor properties, 597
 - respiratory function, 582
 - side effects, 582
 - technico-commercial status, 546
 - tolerance in asthmatic subjects, 571
- Blacks, lisinopril vs. atenolol for hypertension, 775-781
- Blood cholesterol, and hypertension, 974
- Blood lipids, beta blocker effect, 581-582, 583
- Blood pressure
- increased by angiotensin receptor stimulation, 120, 121
 - neuropeptide Y induced long-lasting increase, 125-126
 - xamoterol effect, 567
- Blood pressure profile, nicardipine slow-release and nifedipine slow-release giving lower level, 647-653
- Blood pressure variability, not affected by nicardipine slow-release or nifedipine slow-release, 647, 649-650, 652-653
- BMV-20844, 768
- Bopindolol
- antihypertensive mechanism, 580
 - characteristics, 579
 - effect on blood lipids, 582
 - efficacy, 580
 - pharmacokinetics, 582
 - respiratory function, 582
 - side effects, 582
 - technico-commercial status, 546
- Bradyarrhythmias, therapy for the elderly, 450
- Bradycardia
- causing occurrence of torsades de pointes, 509, 510, 511
 - preexisting proarrhythmia, 518-520, 523
- Bradycardic agent, effect on isolated blood-perfused canine heart, 481-487
- Bradycardia-tachycardia syndrome, digitalis for atrial fibrillation contraindicated, 618
- Bretylum
- chemical defibrillation in humans, 198
 - for treatment of torsades de pointes, 512
 - QT-prolongation and ventricular arrhythmias, 522
- Briserin, for hypertension, 975
- British Hypertension Society Guidelines, 979, 980, 981
- Bucindolol
- characteristics, 579
 - effect on blood lipids, 581, 582
 - efficacy, 580
 - receptor properties, characteristics, and side effects, 597-599
 - respiratory effects, 569
 - technico-commercial status, 546
- Bufuralol
- characteristics, 579
 - negative chronotropic effect, 600
 - receptor properties, 597
- Bunazosin, not inhibiting FABP leakage during hypoxia, 1021, 1023, 1025
- Bunitrolol
- characteristics, 579
 - hemodynamic effects, 606
- Bupranolol, effect on triggered arrhythmias in dogs, 814
- Butofilolol, technico-commercial status, 546
- BW A 575c, comparative beta blocker classification, 564
- Caffeine
- aggravating triggered arrhythmias in dogs, 812, 815
 - effect on contractions of rose-bengal-treated hearts, 228
 - protection against aftercontractions and afterdepolarizations, 863, 864
 - to inhibit calcium in reperfusion injury, 241

- Calcitonin gene related peptide (CGRP)
 anatomic distribution, 122-123
 biochemistry, 121-122
 mechanism of action, 123-124
 role in cardiovascular regulation, 119, 121-124
- Calcium, 314-315
 decreased by propionyl-L-carnitine in cytoplasm of endothelial cells, 97, 100-104
 excess accumulation in reperfusion period, 223
 extracellular, and milrinone effects in neonates, 1017, 1018
 gained in reperfusion period of myocardial stunning, 895-898
 influx increased during hypoxia, 1025
 intracellular, increased by inotropes, 961, 965
 intracellular increase upon reperfusion, 949-950, 953
 ion-force relationship, 962-964, 965
 and myocardial stunning, 942
 neuropeptide Y effect on metabolism in vascular tissues, 127
 overload transient in myocardial stunning, 853, 855, 863-869
 pathogenetic role in myocardial stunning, 259-260, 891-892
 perfusate concentration, 241-242
 propionyl-L-carnitine prevention of overload in mitochondria, 57, 58, 61-64
 as rate-limiting factor for hemodynamic effects of propionyl-L-carnitine, 19, 21, 22
 relationship with free fatty acids in intercellular level in rat hearts, 753-760
 role in regulating smooth muscle contraction with variant angina, 678
 role in reperfusion injury, 237-245
 vasoconstrictor effects of sympathetic activation dependent on, 645-646
- Calcium antagonists, 979
 acute myocardial infarction (book review), 1050
 antiarrhythmic agents and atrial fibrillation, 617-624
 antiarrhythmic drugs and their effects on canine triggered arrhythmias, 813-816
 causing protection to increase the reduction of creatine kinase leakage, and calcium entry into the cytosol, 302, 303, 306
 clemizem cardiovascular effects vs. plasma and myocardial levels, 997-1002
 as coronary artery disease therapy for the elderly, 450
 diltiazem slow-release ambulatory blood pressure profile in hypertension, 701-706
 effect on blood pressure with beta blockers, 569
 effect on neuropeptide Y-induced contraction of cerebral coronary, 127
 effects on extracellular potassium accumulation during ischemia in rats, 1035-1040
 for hypertension, 975, 977, 984
 improving postischemic contractile function, 947-950
 inhibiting FABP to prevent cell death, 1021, 1023, 1025
 and kidneys (book review), 659
 and myocardial infarction, 667-669
 and myocardial ischemia (157-162) 367-368, (P482-P496) 419-421
 myocardial stunning, 849-850, 868, 895-898, 904, 942-943
 myocardial stunning and molecular mechanisms, 926-927
 nisoldipine effect in stress-induced renin-angiotensin-aldosterone activation, 643-646
 protective effects against imipramine intoxication in rats, 489-494
 secondary postinfarct prevention, 1050
 tiapamil limitation on infarct size in acute myocardial infarction, 85-86
 to inhibit calcium in reperfusion injury, 241
 to prevent fatal ventricular arrhythmias, 672
 to relieve "stunning" in reperfusion injury, 244-245
 vs. beta blockers in preventing sudden death, 673-674
 via terminal cardioplegia, 731
- Calcium channels
 alpha blockers, 987
 L-type, propionyl-L-carnitine effect in human heart sarcolemma, 31-35
- Calcium handling proteins, myocardial stunning and molecular mechanisms, 926-927
- Calcium homeostasis, 950
 adenosine restoration of, and myocardial stunning, 903-905
 oxygen-derived free radicals and their effect, 249-264
- Calcium (low Ca^{2+} medium) (LCM), similar protective activity as calcium antagonists in ischemic rat hearts, 1035, 1037-1040
- Calcium overload
 predisposition to ventricular fibrillation, 671, 672
 relationship with free fatty acids in intercellular level in rat hearts, 753-760
- Calcium paradox, myocardial stunning, 861
- Calcium sensitizers, inotropic agents for heart failure, 961-965
- Canine heart, UL-FS49 effect on sinus node cells and smooth muscle and/or myocardial cells, 481
- Capsaicin, systemic treatment effect on calcitonin gene related peptide, 123
- Captopril
 decreased sympathetic activity with benazepril, 749
 end-stage heart failure, 963
 for hypertension, 583, 975
 matrix of factors for evaluation, 572
 mitigating postischemic dysfunction of stunned myocardium, 252
 to ameliorate reperfusion arrhythmias, 244
 vs. captopril hemodynamic effects in conscious normotensive dogs, 635-641
 with hydrochlorothiazide for moderate hypertension in a study with ambulatory monitoring, 153-154
- Carbomoylphosphate synthetase, 12
- Cardiac Arrhythmia Suppression Trial (CAST), antiarrhythmic therapy with ventricular arrhythmia after myocardial infarction studied, 738
- Cardiac catheterization, pulmonary edema treatment with bolus administration of nicardipine, 495-496
- Cardiac efficiency, propionyl-L-carnitine IV hemodynamic study, 107-111
- Cardiac hypertrophy
 beta blocker therapy in hypertension, 577-583
 and heart failure (book review), 163
- Cardiac metabolism
 of propionate, 13-14
 of propionyl-L-carnitine, 13-14
- Cardiac output
 decreased by beta blockers, 577-578, 580
 decreased by propranolol, 577-578
 nebulol effect on cardiovascular hemodynamics, 710, 712-713, 715-716
 nifedipine for angina pectoris, 685-686
 not decreased by UL-FS49 in the canine heart, 486
- Cardiac Purkinje fibers, electrophysiologic effects of FPL 13210 vs. disopyramide in canines, 139-146
- Cardiac surgery, 942
 and myocardial stunning, 879, 883-887
- Cardiac transplantation, 942
- Cardiomyopathy
 beta receptor antagonists reducing symptoms and increasing exercise capacity, 589-601
 nicardipine for pulmonary edema during cardiac catheterization, 495-496
- Cardioplegia, effect of pharmacologic agents upon postischemic recovery, 301-307
- Cardioplegic arrest
 L-carnitine having no protective effect, 57, 77
 open-heart surgery, 942
- Cardiopulmonary bypass surgery, and myocardial stunning, 901
- Cardiovascular hemodynamics, nebulol influence, 709-716

- Cardiovascular pharmacology (book review), 659
- Cardiovascular system, neuropeptide role, 119-127
- Carnitine; *see also* L-carnitine (under L)
effect beneficial on ischemic hearts, 25, 27-29
electrophysiologic derangements elicited by myocardial ischemia and subsequent reperfusion, 67-75
insufficiency, 13
as metabolic drug, 5
- L-Carnitine, effect on triggered arrhythmias in dogs, 814
- Carnitine acetyl transferase (CAT)
activity toward propionyl CoA, 12-14
conversion of propionyl-CoA to propionyl-L-carnitine, 7
necessary for reaction resulting in propionyl-L-carnitine, 5
- Carnitine translocase, 12
- Carteolol
comparative beta blocker classification, 564
technico-commercial status, 546
- Carvedilol
alpha beta blocker, 570
antihypertensive mechanism, 580
beta blocker therapy in the elderly, 582
cardiac function, 580
characteristics, 578, 579
clinical evaluation programs, 573
comparative beta blocker classification, 564
effect on triggered arrhythmias in dogs, 810, 813
efficacy, 580
kinetics, 570
metabolic effects, 572
pharmacokinetics, 582
receptor properties, characteristics, and effects, 597, 600
technico-commercial status, 546
tolerance, 571
- Catalase
adenosine and myocardial stunning, 905-906
effect on myocardial production of free radicals, 258
enhancing recovery of function after reperfusion, 250, 252-255, 257-259, 263
induction of reperfusion measured by electron spin resonance, 289-294
and myocardial stunning, 855-859, 864, 865, 896
myocardial stunning and molecular mechanisms, 927
neutrophils and myocardial stunning, 909, 916, 919
protective effect in reperfusion-induced arrhythmias of rat hearts, 227, 228, 230, 231
- Catecholamines, 517, 519
beta-receptor antagonists in heart failure, 590, 594-596
calcium overload with imipramine intoxication, 492, 494
chlorthalidate effect on myocardium, 524
heart beta adrenoceptor function is to modulate, 549, 551-557
and myocardial stunning, 903, 904
new beta blockers and clinical outcomes, 566
perindoprilat effect during coronary artery occlusion and reperfusion in dogs, 1048
perindopril vs. chlorothiazide therapy effect with infarction, 147-151
posttreatment for CABG to influence cardiac performance, 299
reversing contractions dysfunction in neonates, 1012
role in cell death during hypoxia, 1025
role in development of afterpotentials in ventricular tissue, 203, 209, 210
urapidil electrophysiological effects, 988, 990
- Celiprolol
beta blocker therapy in the elderly, 582
characteristics, 578, 579, 583
comparative beta blocker classification, 564
effect on blood lipids, 581, 582
efficacy, 580
for asthmatic patients, 573
hemodynamic interactions with nifedipine in angina pectoris, 681-686
kinetics, 570
left ventricular hypertrophy, 581
lesser effects on bronchial function and lipoprotein profiles, 561
matrix of factors for evaluation, 572
metabolic effects, 572
nonadrenoceptor vasodilators, 570
partial agonist activity, 567
pharmacokinetics, 582
receptor properties, characteristics, and effects, 597, 599-600
reducing beta₂ receptors, 594
resistance arterial changes, 581
respiratory effects, 569, 582
side effects, 582
technico-commercial status, 546
tolerance, 571
tolerance in asthmatic subjects, 571
- Cellular redox state, 862, 863
- Cesium
to elicit EADS by prolonging repolarization, 210
to produce experimentally early after depolarizations, 201-202
- Cetamolol
characteristics, 579
pharmacokinetics, 582
technico-commercial status, 546
- CGP 20172 A, beta-blocker evaluated only in volunteers, 565
- Chemotherapeutic agents, QT prolongation and proarrhythmic risk, 524
- Choline, effect on human endothelial cells, 101
- Chlorthalidate, QT prolongation and proarrhythmic risk, 523-524
- Chloroquin, QT prolongation and proarrhythmic risk, 524
- Chlorothiazide, effect on cardiac hypertrophy and sympathetic activity, 147-151
- Chlorpromazine
inducing torsades de pointes, 509
QT prolongation and proarrhythmic risk, 523
- Chronotropic effects, milrinone in neonatal pig hearts, 1011, 1016, 1018
- Cibenzoline, effect on triggered arrhythmias in dogs, 809, 813
- Cicloprolol
characteristics, 579
heart size reduced, 601
receptor properties, characteristics, and effects, 597, 599
- Cirrhosis, encainide pharmacokinetics in patients, 733-738
- (+) Cis-diltiazem, binding sites evaluated to see propionyl-L-carnitine effect, 33-34
- Class I antiarrhythmic agents
combined effect of \dot{V}_{max} of action potentials, 791-799
combined use effects on depolarization maximum rate, 801-804
- Class III antiarrhythmic agents
potassium channel blocking properties seen with QT-interval, 517, 519
sotalol and isomers hemodynamic effects, 1027-1032
- Clentiazem (TA-3090)
cardiovascular effects vs. plasma and myocardial levels, 997-1002
structural formula, 998
vasodilator effects, 998, 1000, 1002
- Clinical trials, meta-analysis of hypertension treatment, 983
- Clofilium, QT prolongation, 524
- Clonidine
hemodynamic response, 971
long-term effects, 972
- Chloranolol, technico-commercial status, 546
- Coenzyme Q₁₀, 314
effect on triggered arrhythmias in dogs, 814
effect upon myocardial protection, 301, 304-307
induction of reperfusion measured by electron spin resonance, 289-294

- oxygen free radical formation during reperfusion, 280
- pretreatment in enhance intraoperative myocardial protection in CABG patients, 297-300
- Combination therapy
- antiarrhythmic agents for ventricular arrhythmias, 827-833
 - class I antiarrhythmic agent effects on V_{max} , 801-804
 - disopyramide with mexiletine for ventricular premature beats, 835-840
 - use-dependent block percent increased with class I antiarrhythmic agents, 791-799
- Congestive heart failure, (321-326) 389-390, (455-460) 411-412, (P19-P33) 329-331, (P163-P177) 369-371, (P467-P481) 415-417
- amiloride added to digoxin affecting hemodynamics, 719-724
 - beta blockade harmful effects, 596
 - beta blockade preferred to calcium antagonism, 673-674
 - beta-blocker long-term therapy for dilated cardiomyopathy, 463-467
 - beta-receptor antagonists, 589-601
 - cardiovascular pharmacology (book review), 659
 - enoximone therapy, 695
 - factors influencing the response to beta blockers, 600
 - following diltiazem use, 672, 673
 - milrinone effect on neonates, 1018
 - molsidomine acute hemodynamic effects in patients with ischemic cardiomyopathy, 155-156
 - moxonidine, 972
 - and myocardial stunning, 886
 - perindoprilat effect, 1047-1048
 - renin-angiotensin-aldosterone (RAA) involvement in pathophysiology, 643, 645, 646
 - with coronary bypass surgery in elderly, 451, 453
- Conscious dogs, nicorandil vs. nitroglycerin coronary effects, 131-137
- Contractile function, recovery enhanced by calcium antagonists, 947
- Contractile proteins, phosphorylation done by elevated calcium, 892
- Converting enzyme activity (CEA), benazepril effect on sino-aortic baroreceptor heart rate reflex, 748
- Coronary angioplasty, nitroglycerin IV pretreatment to improve ischemic tolerance, 497-500
- Coronary arteries, molsidomine metabolite SIN-1 effect in sheep, 769-773
- Coronary artery bypass grafting (CABG) bisoprolol hemodynamic evaluation with altered LV function, 629-632
- coenzyme Q_{10} pretreatment for myocardial protection, 297-300
 - expenditures in U.S. annually, 449
 - percentage of elderly, 449-453
- Coronary artery diameter, nicorandil vs. nitroglycerin, 131-137
- Coronary artery disease
- antihypertensive therapy, 980
 - beta blocker therapy, 572, 573
 - enoximone hemodynamic and antiischemic effects, 689-695
 - glutathione autooxidation and oxidative stress during reperfusion, 283
 - hemodynamic changes by propionyl-L-carnitine, 5
 - in patients in studies with beta blockers in heart failure, 591
 - isoproterenol possibly precipitating an acute coronary event, 511
 - molsidomine acute hemodynamic effects in patients with ischemic cardiomyopathy, 155-156
 - and myocardial stunning, 877, 880, 881, 883, 886-887
 - nifedipine, celiprolol, and combination therapy, 681-686
 - nutritional factors and hyperinsulinemia, 1045
 - reperfusion injury and oxygen-derived free radicals, 249, 250
 - treatment in the elderly, 449-453
- Coronary artery occlusion, perindoprilat effect in dogs, 1047-1048
- Coronary artery spasm, 942
- consequence of reductions of tissue magnesium, 677-680
- Coronary blood flow
- adenosine effect, 903, 904, 906
 - clentiazem effects, 997-1002
 - during reperfusion period due to nicorandil-Mg terminal cardioplegic solution, 728-729
 - nicorandil effect greater than nitroglycerin on dogs, 131-137
 - oxyfedrine effect, 991-995
 - propionyl-L-carnitine IV short-term effects in dogs, 45, 51-55
- Coronary bypass surgery, and myocardial stunning, 879, 883-886
- Coronary heart disease (CHD)
- antihypertensive therapy, 973-978
 - and myocardial stunning, 229
 - nicardipine slow-release vs. nifedipine slow-release for hypertension, 647-653
 - nonpharmacologic measures for lowering blood pressure, 157-158
 - nutritional factors and hyperinsulinemia, 1045
 - pharmacologic treatment of atrial fibrillation, 617
- Coronary ligation-induced arrhythmia, antiarrhythmic drug effects, 805-816
- Coronary resistance, UL-FS 49 effect on dogs, 481, 485-486
- Coronary sinus, pharmacokinetic analysis of retroinfusion using metoprolol as tracer, 1005-1010
- Coronary thrombolysis, myocardial stunning, 849
- Coronary vascular resistance, neutrophils and myocardial stunning, 917-918
- Counterclockwise hysteresis, 1002
- Creatine phosphate (CP)
- CP overshoot, 933, 934, 936
 - and hibernating myocardium, 940-941
 - role in treatment of myocardial stunning, 901-902
- Creatine phosphokinase (CPK)
- propionyl-L-carnitine effect on ischemic rabbits, 57-60, 62-64
 - propionyl-L-carnitine with tiapamil in myocardial infarction, 90
- CV-3611 (2-O-octadecylascorbic acid), induction of reperfusion measured by electron spin resonance, 289-294
- Cyanide, to inhibit calcium in reperfusion injury, 241
- Cyclophosphamide
- immunosuppressive therapy for viral myocarditis, 477
 - neutrophils and myocardial stunning, 919
- Cyclosporine
- immunosuppressive therapy for viral myocarditis, 477
 - QT prolongation and proarrhythmic risk, 524
- D-888 (desmethoxyverapamil), binding sites evaluated to see propionyl-L-carnitine effect, 31, 33-35
- DAVIT-II trial
- verapamil beneficial to post-infarct patients, 671, 672
 - verapamil double-blind multicenter trial, 669
- D-carnitine
- acylcarnitine transfer, 8
 - effect on human endothelial cells, 100, 101, 103
- Deferoxamine, myocardial stunning and molecular mechanisms, 927
- Delayed afterdepolarizations (DADs) reperfusion-induced injury, 228
- torsades de pointes, 208-210
- Delayed no-reflow, calcium accumulation effect during reperfusion period, 240-241, 244, 245
- Delayed repolarization syndrome, 191, 198, 199, 202
- Delivalol, withdrawal from market because of hepatic dysfunction episodes, 547
- Demand for $\sim P$, ischemic preconditioning, 934-936
- Denopamine, 556
- 5-Deoxyadenosylcobalamine, 11
- Deoxycarnitine, acylcarnitine transfer, 8

- Depolarization maximum rate (\dot{V}_{max})
 class I antiarrhythmic agent combined effects on \dot{V}_{max} of action potentials, 791-799
 class I antiarrhythmic agent effects on guinea-pig ventricular muscles, 801-804
 urapidil electrophysiological effects, 988-990
- Depolarizations, linked to torsades de pointes, 201-202
- Depolarized muscle, urapidil electrophysiological effects, 988-990
- Desferal, intervention studied with arrhythmogenesis, 228
- Desferrioxamine
 attenuating postischemic myocardial dysfunction, 250, 252, 254
 for myocardial stunning, 887
 myocardial infarct size affected, 263
 and myocardial stunning, 857, 859, 860, 864, 909, 943
- Desmethoxyverapamil (D-888), binding sites evaluated to see propionyl-L-carnitine effect, 31, 33-34
- o-Desmethyl encainide (ODE), effect on ADP/5-HT induced platelet aggregation and in canine intravascular thrombosis, 763-768
- Diabetes mellitus
 beta blocker assessment criteria, 563
 cardioselective agents, 578
 OK 432 preventive effect, 471
 oxyfedrine effect on three-vessel disease, 992
 as result of antihypertensive drug therapy, 164
- Diabetics
 acute myocardial infarction (book review), 1050
 beta blocker metabolic effects, 571-572
 beta blocker therapy, 581
 nutritional factors and coronary heart disease, 1045
 propranolol use, 577
 verapamil treatment, 669
- Diastolic dysfunction, as component of myocardial stunning, 850
- Diazoxide, effect on blood pressure with beta blockers, 569
- Dibenzamine, antiarrhythmic effect, 987
- Dibenzylamine, vasodilation induced, 607
- Dibenzepin, chemical defibrillation in humans, 198
- Dichloroisoproterenol, 561, 566-567
- Diet, hyperinsulinemia and coronary heart disease, 1045
- Digitalis
 atrial fibrillation therapy when heart failure present, 617-618, 620-624
 congestive heart failure treatment, 719, 722-724
 increasing myoplasmic calcium, 961, 962
 long-term treatment of heart failure, 589, 598
- Digitalis-induced arrhythmia, antiarrhythmic drug effects, 805-816
- Digoxin
 characteristics and effects, 597
 as coronary artery disease therapy for elderly, 450
 inotropic action not decreased by amiloride addition, 719, 721-724
- Dihydropyridines, 31, 551, 667
- Dilated cardiomyopathy (DCM), 463-467
- Dilazep, 813, 815
- Dilevalol
 acute and chronic effects, 582, 610-611
 antihypertensive mechanism, 580
 beta₂ adrenoceptor stimulation, 569-570
 beta blocker therapy in the elderly, 582
 blood pressure reduction, 568, 605, 612, 613
 characteristics, 578, 579
 compared to other beta blockers, 568
 effect on blood lipids, 582
 efficacy, 580
 hemodynamics effect, 606, 610-613
 improved arterial compliance, 581
 kinetics, 570
 left ventricular hypertrophy, 581
 metabolic effects, 572
 partial agonist activity, 567
 pharmacokinetics, 582
 receptor properties, characteristics, and effects, 597, 600
 resistance arterial changes, 581
 respiratory function, 582
 sporadic hepatic damage causing withdrawal from market, 573
 technico-commercial status, 546
 tolerance, 571
- Diltiazem, 314
 ambulatory blood pressure profile of slow-release, 701-706
 binding sites evaluated to see propionyl-L-carnitine effect, 31, 33-35
 as calcium antagonist during test of hemodynamic effects of PLC, 46, 51-53
 cardiovascular effects in dogs, 997
 effect on triggered arrhythmias in dogs, 810, 814
 enhancing recovery of contractile function, 947-948, 950
 extracellular potassium accumulation, 1035, 1037-1040
 for acute myocardial infarction, 667-669
 improving recovery after ischemia, 259
 and myocardial stunning, 895-896
 nighttime blood pressure not markedly reduced, 706
- not able to stop ventricular arrhythmias with reperfusion, 245
 pharmacologic treatment for atrial fibrillation, 617, 619-624
 preventing cardiac events, 668
 treatment of acute ischemic syndromes, 668
 vs. clonazepam, 1000, 1002
- Dimethylthiourea (DMTU)
 improved function of the postischemic myocardium, 251, 252
 and myocardial stunning, 856, 857, 909
 to attenuate postischemic contractile dysfunction, 229-230
- Diphenylhydantoin, single-drug therapy in Japan for VPs, 838
- Dipyridamole, 768, 994
 effect on response to SIN-1 in human vena saphena magna, 457-461
- Disopyramide
 antiarrhythmic efficacy and proarrhythmic risk, 519, 520, 524
 atrial fibrillation therapy, 617, 621-623
 effect on triggered arrhythmias in dogs, 810-812, 814, 815
 for ventricular premature beats, 835-840
 for ventricular arrhythmias, 827-833
 inducing torsades de pointes, 505, 506, 509
 side effects, 827, 838-840
 single-drug therapy in Japan for VPs, 838
 vs. FPL 13210 electrophysiologic effects, 139-146
 with flecainide to affect use-dependent block of \dot{V}_{max} , 791-796, 798
 with lidocaine to affect use-dependent block of \dot{V}_{max} , 791-798
 with mexiletine effects on \dot{V}_{max} , 801-802
 with mexiletine for ventricular arrhythmias, 827-833
 with mexiletine to affect use-dependent block of \dot{V}_{max} , 791, 793-796, 798
- Diuretics
 compared to perindopril for effects following myocardial infarction, 147-151
 as coronary artery disease therapy for elderly, 450
 cost, 980
 for hypertension, 974-975, 977
 QT prolongation and proarrhythmic risk, 524
 xipamide hormonal effects in healthy men, 741-745
- Dobutamine, 555
 acute myocardial infarction, 1050
 infused during study of heart function and myocardial stunning, 910
 postoperative administration in CABG, 298, 299

- to stimulate contraction of stunned myocardium, 950
- Dog hearts
 - benazepril hemodynamic effects, 635-641
 - radical scavenger effects on reperfusion-induced arrhythmias, 289-295
 - perindoprilat effect during coronary artery occlusion and reperfusion, 1047-1048
- Dopamine, 552, 556
 - acute myocardial infarction, 1050 and myocardial stunning, 885, 942
 - to stimulate contraction of stunned myocardium, 950
- Dopexamine, 552
- Doxazosin
 - blood pressure reduction, 605
 - hemodynamics effect, 606, 608
 - total peripheral resistance index affected, 608, 612
- Doxepine, QT prolongation and proarrhythmic risk, 523
- DPI 201-106, end-stage heart failure, 962, 965
- Drug interactions, celiprolol with nifedipine in angina pectoris, 681-686
- Drug reactions, and drug therapy (7-12) 325-326, (76-81) 343-344, (P333-P347) 393-395
- Drug therapy, and adverse drug reactions (7-12) 325-326, (76-81) 343-344, (P333-P347) 393-395
- Dyazide, for hypertension, 975
- E-0747 (antiarrhythmic drug), 809, 813, 815
- E-4031, 813, 815
- Early afterdepolarizations (EADs)
 - QT-interval prolonging drugs, 518-520, 522
 - suppressed by magnesium, 506
 - torsades de pointes, 201-202, 205-210, 531-536
- Echocardiography
 - to evaluate effectiveness of long-term beta-blocker therapy for dilated cardiomyopathy, 463-467
 - unstable angina and myocardial stunning, 880-881, 885
- Effective antiarrhythmic plasma concentration, antiarrhythmic drug monotherapy effect on dogs, 805-816
- Eicosanoid synthesis, occurring largely in right cardiac atrium of rabbits and rats, 656
- Eisai Satellite Symposium: Reperfusion Injury (Feb., 1990), 223-224
- Elderly
 - antihypertensive therapy, 979, 983-984
 - beta blocker therapy and hypertension, 582
- coronary artery disease therapies, 449-453
- lisinopril vs. atenolol for hypertension, 775, 779-781
- sublingual administration of ketanserin for hypertension, 699
- Electrocardiography
 - book review (Derek J. Rowlands), 1049
 - continuous electrical activity, 182-190
 - electrocardiogram amplitude progressive variations, 171-190
 - propionyl-L-carnitine IV hemodynamics effects, 48, 50, 52-54
 - QT-prolongation as manifestation of torsades de pointes, 201-202
 - torsades de pointes classification scheme, 192-199
 - torsades de pointes description, 171-182
 - torsades de pointes warning signs, 510
- Electrolyte imbalance, atrial fibrillation, 617
- Electron paramagnetic spin resonance (EPR) spectroscopy, 313
 - free radical formation upon reperfusion, 909, 919
 - and myocardial stunning, 904
- PBN radical adducts detected in coronary venous effluent blood in open-chest dogs, 255-256, 258
- to identify and measure free radicals, 279-280, 858, 859, 949
- to study effects of radical scavengers on reperfusion-induced arrhythmias, 289-295
- to study mitochondria free radical effects on reperfusion-induced arrhythmias and reperfusion, 289-295
- Enalapril
 - for hypertension, 583, 975
 - with hydrochlorothiazide for hypertension, 153-154
- Encainide
 - antiarrhythmic efficacy and proarrhythmic risk, 519, 521
 - effect on ADP/5-HT induced platelet aggregation and in canine intravascular thrombosis, 763-768
 - not used for ventricular arrhythmias after myocardial infarction, 738
 - pharmacokinetics with cirrhosis, 733-738
- Encephalomyocarditis (EMC) virus, preventive effects of OK432 on murine acute myocarditis, 471-479
- Endomyocardial biopsy, to determine acute or chronic myocarditis in study, 464, 467
- Endothelial cells
 - molsidomine metabolite SIN-1 effect on sheep, 769-773
 - propionyl-L-carnitine protective effect in humans, 97-104
- Endothelial-derived relaxing factor (EDRF)
 - involved in mediation of the vascular effects of CGRP, 123
 - neutrophils and myocardial stunning, 918, 919
- Endothelial dysfunction, neutrophils and myocardial stunning, 915
- Enoximone, coronary artery disease, 689-695
- Enzyme induction, none observed following oral doses of encainide in cirrhotic patients, 733-738
- Epanolol
 - characteristics, 579
 - compared to other beta blockers, 568
 - efficacy, 580
 - fatigue incidence, 569
 - partial agonist activity, 567, 568
 - technico-commercial status, 546
- Epidemiology, 979-980
- Epinephrine, and myocardial stunning, 942
- Erythrocytes, magnesium content in patients with vasospastic angina, 677-680
- Erythro-9-[2-hydroxy-3-nonyl] adenine (EHNA), 905
- Erythromycin, QT prolongation and ventricular tachycardia, 524
- Esmolol
 - atrial fibrillation therapy, 620
 - characteristics, 578, 579
 - comparative beta blocker classification, 564
 - and myocardial stunning, 943
 - receptor properties, characteristics, and effects, 597, 599
 - subclassification in pharmacologic properties, 564
 - technico-commercial status, 546
- Essential hypertension, moxonidine hemodynamic and neurohumoral effects, 967-972
- Etacizin (NIK-244), 810-811, 814
- Exercise
 - and atrial fibrillation, 620
 - and blood pressure control, 977
 - capacity during beta-blocker therapy in heart failure, 589-601
 - drug action at adrenergic receptors, 605-614
 - inducing myocardial ischemia and myocardial stunning, 880, 886
 - moxonidine effect on essential hypertension patients, 967-972
- Exercise ECG, enoximone hemodynamic and antiischemic effects in coronary artery disease, 689-695
- Extracellular acidosis, to inhibit sodium-calcium exchange in reperfusion injury, 242
- Fatty acid binding protein (FABP)
 - carrier protein, receptor for, and

- bound to free fatty acids, 753-757, 759
- leakage during hypoxia, 1021-1026
- Felodipine
- helping prevent or improve left ventricular failure, 672-673
 - protective effects superior to verapamil against imipramine intoxication in rats, 489-494
 - reducing ambulatory blood pressure, 705
- Fenoxodil, QT prolongation, 524
- Flecainide
- antiarrhythmic efficacy and proarrhythmic risk, 519-521, 524
 - atrial fibrillation therapy, 617, 621-624
 - effect on ADP/5-HT induced platelet aggregation and in canine intravascular thrombosis, 763-768
 - effect on triggered arrhythmias in dogs, 809, 813, 815
 - with disopyramide to affect use-dependent block of \dot{V}_{max} , 791-796, 798
 - with mexiletine effects on \dot{V}_{max} , 801-803
 - with mexiletine to affect use-dependent block of \dot{V}_{max} , 791, 793, 795-797
- Flestolol
- characteristics, 579
 - comparative beta blocker classification, 564
 - technico-commercial status, 546
- Flunarizine, protective effects against imipramine intoxication in rats, 489, 493-494
- FPL 13210
- concentration-response relation and concentration-dependent effects, 140-141
 - disopyramide derivative electrophysiologic effects and \dot{V}_{max} in dogs, 139-146
 - less likely to produce cardiodynamic disturbances than disopyramide, 139
- Frank-Starling mechanism, 22, 961
- Free fatty acid (FFA)
- relationship between elevation, calcium, and ventricular arrhythmias in perfused rat hearts, 753-760
 - relationship with intracellular Ca^{2+} level, 760
- Free radicals
- association with postischemic contractile function, 855-856, 859
 - calcium uptake in myocardial stunning, 895-898
 - as cause of reperfusion arrhythmias, 237, 241, 245
 - cellular actions, 862
 - formation reduced by propionyl-L-carnitine, 77-82
 - harmful effects due to multiple membrane damage, 895
 - inducing injuries as mechanism of myocardial stunning, 855
 - injury to ischemic reperfused myocardium and alpha-tocopherol levels, 309
 - and myocardial stunning, 313-315, 856-869, 909, 912
 - neutrophil-derived, 865
 - neutrophils and myocardial stunning, 915-916
 - possible role in reperfusion arrhythmias, 223
 - relation with reperfusion-induced arrhythmias in the canine heart, 289-295
 - and reperfusion-induced injury, 225-232
 - with adenosine in myocardial stunning, 903-905
- Free-radical scavengers
- myocardial stunning, 849, 850
 - via terminal cardioplegia, 731
- Frusemide, with metoprolol in ischemic heart disease studies, 593, 594
- Gabexate mesilate (FOY), effect upon myocardial protection, 301, 303-307
- Gallopamil
- effect on triggered arrhythmias in dogs, 810, 814
 - extracellular potassium accumulation in rats, 1040
 - pharmacologic treatment for atrial fibrillation, 617, 619-624
- Gastroenterological disease, pharmacologic treatment of atrial fibrillation, 617
- Glaucoma, disopyramide adverse extracardiac effects, 139
- Global ischemia
- calcium antagonists effects on extracellular potassium accumulation in rats, 1035-1040
 - reperfusion injury prevented by coenzyme Q_{10} with CABG, 297-300
- Glomerular filtration rate (GFR)
- propionyl-L-carnitine IV effect, 51, 52, 55
- Glucose
- damage to human umbilical vein as result of testing effect of propionyl-L-carnitine, 99-100
 - modulating effect on propionate suggested, 41, 42
- Glutathione
- intervention studied with arrhythmogenesis, 228, 232
 - role in myocardial metabolism and index of oxidative stress, 280-285
- Glyceraldehyde phosphate dehydrogenase (GAPDH), 929
- Glyceryl trinitrate (GTN), vs. molsidomine SIN-1 in coronary arteries and peripheral vessels of sheep, 769-773
- Glycolysis, rate related to intracellular calcium control, 237-239
- Goat anticanine neutrophil serum, 911
- G proteins, coupled with beta adrenoceptors in heart, 549-557
- Guanethidine, 126
- Haber-Weiss reaction, 857
- Halothane, role in triggered arrhythmias, 808
- Heart failure
- beta blocker therapy, 572
 - beta receptor antagonists for therapy, 589-601
 - and cardiac hypertrophy (book review), 163
 - diuretics effects on sympathetic activity and correlation with plasma norepinephrine levels, 151
 - end-stage, and calcium-sensitizing inotropic agents, 961-965
 - with beta blocking therapy, 568
- Heat-shock proteins
- ischemic preconditioning, 937
 - and myocardial stunning, 929-930
- Hemochromatosis, cirrhosis and encaidine pharmacokinetics, 734
- Hemodynamics
- amiloride addition effect on digoxin for chronic heart failure, 719-724
 - benazepril effect in dogs, 635-641
 - beta blocker effect, 605-614
 - bisoprolol effect on CABG with altered LV function, 629-632
 - clentiazem effects, 997-1002
 - coronary sinus retroinfusion using metoprolol as tracer, 1005-1010
 - drug interactions of celiprolol and nifedipine in angina pectoris, 681-686
 - enoximone effect in patients with coronary artery disease, 689-695
 - molsidomine acute effects with ischemic cardiomyopathy, 155-156
 - moxonidine effects on essential hypertension patients, 967-972
 - nicorandil effects on dogs, 131-137
 - nitroglycerin effects on chronic conscious dogs, 131-137
 - oxyfedrine for angina pectoris, 993-995
 - trimetazidine antianginal action, 1043-1044
- Hepatitis, cirrhosis and encaidine pharmacokinetics, 734
- Hibernating myocardium, 939-943
- High-density lipoproteins (HDL), protective effect on atherosclerotic process, 269-275
- High-energy phosphate (HEP), myocardial stunning, 901-903, 905
- 5HT (5-hydroxytryptamine), contractile response on human vena saphena magna, 458, 459
- Human myocardium
- alpha-tocopherol levels during cardiac surgery, 309-312

- propionyl-L-carnitine effect on L-type calcium channels in sarcolemma, 31-35
- Human recombinant superoxide dismutase, 314
- Hydralazine
effect on blood pressure with beta blockers, 568
end-stage heart failure, 963
and myocardial stunning, 942, 943
- Hydrochlorothiazide (HCTZ)
for hypertension, 975, 977, 983
long-term therapy increasing renin less than short-term, 745
- 3-Hydroxypropionate, 11
- Hydroxyl radicals, exogenous sources administered to laboratory animals, 159
- 5-Hydroxytryptamine, heart beta-adrenoceptor function, 554
- Hypercalcemia, associated with stunning in reperfusion injury, 244
- Hypercholesterolemia, and hypertension, 976, 977
- Hyperglycemia, and hypertension, 977
- Hyperinsulinemia
and hypertension, 976, 977
nutritional factors and coronary heart disease, 1045
- Hypertension, (94-99) 349-350, (100-105) 351-352
angiotensin involved in maintaining, 121
atenolol vs. lisinopril therapy, 775-781
benazepril, 635, 638-639
beta blockers contraindicated, or use with caution, 572
beta blocker therapy, 577-583
calcium antagonists when renal impairment present (book review), 659
captopril, 635, 638-639
clinical, and experimental investigations, (P49-P63) 337-339
clinical, (book review), 164
clinical aspects and therapeutics (P193-P207) 377-379
clinical aspects and therapeutics (P497-P511) 423-425
diltiazem slow-release ambulatory blood pressure profile, 701-706
enalapril, 635
ketanserin sublingual administration effects, 697-699
lisinopril vs. atenolol therapy, 775-781
mild, and determination of at-risk patients, 980
moderate, and captopril/enalapril combined with hydrochlorothiazide in a study with ambulatory monitoring, 153-154
moxonidine hemodynamic and neurohumoral effects, 967-972
nicardipine slow-release vs. nifedipine slow-release with coronary heart disease, 647-653
- nisoldipine suppression of RAA reaction, 646
- nonpharmacologic measures for lowering blood pressure, 157-158
- quinidine with verapamil for AF, 624
- risk factors, 1045
- risks and assessment methods, 976
- salt intake reduction encouraged, 984
- therapy, 973-978, 983-984
- verapamil therapy for atrial fibrillation, 619, 622-624
- with angina pectoris and beta blocker therapy, 607
- Hypertension, Detection and Follow-up Programme (HDFP), 980
- Hyperthyroidism, pharmacologic treatment of atrial fibrillation, 617
- Hypertrophic cardiomyopathy, verapamil therapy for atrial fibrillation, 619
- Hypertrophic obstructive cardiomyopathy, digitalis for atrial fibrillation contraindicated, 618
- Hypertrophy
chlorothiazide not for decreasing, 147
perindopril for reversal or prevention, 147
- Hypoglycemia, propranolol effect on return of plasma glucose, 571
- Hypokalemia
causing torsades de pointes, 509, 510, 512
and hypertension, 977
preexisting proarrhythmia, 518-523
torsades de pointes and early afterdepolarizations, 531, 535, 536
- Hypomagnesemia, 518
causing torsades de pointes, 509, 510, 512
- Hypotension
following systemic administration of CGRP, 123, 127
influence on propionyl-L-carnitine effect on hemodynamics in dogs, 48-49, 51, 53
- Hypothermia, 315
ischemic-reperfusion injury and post-ischemic recovery, 301-307
reperfusion and calcium uptake, 896-897
- Hypoxia, fatty acid binding protein leakage, 1021-1026
- ICI 118551
comparative beta blocker classification, 564
lack of hypotensive effect, 578
to determine presence and function of beta₂ adrenoceptors, 565-566
- Idiopathic dilated cardiomyopathy, propionyl-L-carnitine and purified sarcolemma PN binding, 35
- Imidazoline, for essential hypertension, 971
- Imipramine, inducing torsades de pointes, 512
- Imipramine intoxication
felodipine protective effects in anesthetized rats, 489-494
flunarizine protective effects in rats, 489, 493-494
nimodipine protective effects in rats, 489, 493-494
verapamil protective effects in rats, 489-494
- Indenolol, technico-commercial status, 546
- Indolamines, 556
- Inosine (INO)
ischemic preconditioning, 934
and myocardial stunning, 902, 903, 905
- Inotropic effects
agents for calcium-sensitizing, for heart failure, 961-965
amiloride effect on patients taking digoxin, 719-724
calcium antagonists and extracellular potassium accumulation in rats, 1035-1037, 1039-1040
milrinone in neonatal pig hearts, 1011, 1016-1018
sotalol isomers, 1027, 1031, 1032
- Insulin, diet and coronary heart disease, 1045
- Interferon, immunologic activity measured as effect of OK432 on acute myocarditis, 472, 474, 478, 479
- Interleukin-1, neutrophils and myocardial stunning, 916-917
- International Society of Hypertension (ISH), 975, 976, 980, 981
- Intracoronary electrocardiogram, to evaluate IV nitroglycerin effects on ischemic left ventricular dysfunction during coronary angioplasty, 497-500
- Intrinsic sympathomimetic activity (ISA), 590-594, 596, 598-601
beta blockers and blood pressure, 606
bisoprolol after coronary artery surgery, 632
celiprolol for angina pectoris, 681, 685
not in nebivolol, 716
- Ion channels, heart beta-adrenoceptor function, 549-557
- Ionomycine, propionyl-L-carnitine effect on endothelial cells, 100-102
- Irreversible injury, ischemic preconditioning, 933
- Ischemia. *See* Myocardial ischemia
- Ischemia-reperfusion-induced arrhythmia, human high- and low-density lipoprotein effect, 269-275
- Ischemic cardiomyopathy, molsidomine acute hemodynamic effects, 155-156
- Ischemic heart disease
and atrial fibrillation, 620, 624
beta receptor antagonists for treatment of heart failure, 589-590, 592-594, 596, 599-601

- magnesium myocardial content and sudden death, 679
- nisoldipine suppression of RAA reaction, 646
- Ischemic nondilated cardiopathy, verapamil therapy for atrial fibrillation, 619
- Ischemic preconditioning, 933-938; *see also* Myocardial ischemia
- biologic features, 933-934
- metabolic basis, 934-937
- myocardial stunning, 925-927
- Isobutylmethyl-xanthine (IBMX), similar to milrinone effects in neonatal pig hearts, 1011-1017
- Isolated cardiac myocytes, carnitine quantification and effect on electrophysiologic derangements evoked by hypoxia, 68-71
- Isomazole, end-stage heart failure, 962
- D-Isomers, sotalol hemodynamic effects on myocardium, 1027-1032
- L-Isomers, sotalol hemodynamic effects on myocardium, 1027-1032
- Isometric exercise, nebivolol influence on cardiovascular hemodynamics, 709-716
- Isoprenaline, 566-567
- for treatment of torsades de pointes, 201-202
- heart beta-adrenoceptor function, 551, 555, 556
- Isoproterenol (ISP)
- conventional torsades de pointes therapy, 201-202, 506, 509, 511
- for arrhythmias, 198, 199
- induction of EADs, 207
- mechanisms for beneficial effects, 594
- milrinone effect studied in its presence, 1014, 1017
- and myocardial stunning, 942
- to suppress proarrhythmia, 522
- with ryanodine to inhibit EADs and DADs, 210
- Isosorbide dinitrate, effect on ST-segment depression in surface ECG during balloon coronary occlusion, 500
- Isovolumic registration, sotalol isomers effect on LV myocardium, 1028-1031
- Isradipine, binding sites and effect of propionyl-L-carnitine on L-type calcium channels in humans, 31
- Kaplan-Meier test, 473
- Ketanserin
- causing ventricular arrhythmias in some patients, 983
- inhibiting platelet aggregation in patients with cardiovascular diseases, 763, 765
- not to be combined with a diuretic, 164
- QT prolongation and proarrhythmic risk, 523
- sublingual vs. oral administration for hypertensive patients, 697-699
- Kidneys
- and calcium antagonists (book review), 659
- and hypertension, 973, 978
- propionyl-L-carnitine excretion with urine, 13
- reabsorption of carnitine and acylcarnitine elimination, 13
- Krebs cycle
- anaplerotic reaction enhanced by propionyl-L-carnitine, 22
- effect of propionyl-L-carnitine, 13, 14
- Kruskal-Wallis test, 473
- KT-362 (antiarrhythmic drug), effect on triggered arrhythmias in dogs, 809, 813, 815
- Labeled propionate oxidation, effect in aerobic myocardium, and dose-response relationship, 37-42
- Labetalol
- alpha adrenoceptor blockade, 570
- antihypertensive efficacy of vasodilator beta blocking, 570
- blood pressure reduction, 612
- dilevalol as its R' · R isomer, 570
- hemodynamics effect, 606, 609-610, 613
- receptor properties, characteristics, and effects, 597, 598
- side effects, 582
- Laboratory diets, superoxide anions, hydroxyl radicals and antioxidants in diets possibly distorting test results in animals, 159
- L-acetyl-carnitine, chronic administration
- effect on rabbit heart mechanical function, 18-22
- Lambeth Conventions
- ECG classification of arrhythmias, 202
- recommendation that arrhythmia classification be based solely on ECG, 191-199
- L-carnitine
- chronic administration effect on rabbit heart mechanical function, 18-22
- effect of derivatives on heart membrane ATPases, 25-29
- effect on ¹⁴C-palmitate oxidation by cardiac homogenate and myocytes, 81
- effect on fatty acid-supplemented ischemic pig hearts, 77, 79-80
- effect on globally ischemic pig heart, 57
- effect on heart mitochondrial superoxide formation, 81, 82
- effect on human endothelial cells, 100-103
- effect on isolated heart, 57
- effect on open-chest regional ischemic dog myocardium, 57
- hemodynamic effects in anesthetized dogs, 45-46, 48, 50-55
- inert effect for ischemia and reperfusion in rabbit hearts, 63
- protective action in ischemia and reperfusion, 57
- vs. propionyl-L-carnitine, 5, 31
- Left circumflex coronary (LCX) artery, pharmacokinetic analysis of coronary sinus retroinfusion using metoprolol, 1005-1010
- Left main coronary disease, greater frequency in the elderly, 450
- Left ventricular contractility, decreased by UL-FS 49, 486
- Left ventricular (LV) dysfunction
- beta-blocker studies in heart failure, 591
- beta blocker therapy, 600
- betaxolol not causing deterioration in systolic function, 599
- greater frequency in the elderly, 450, 452
- and myocardial stunning, 877, 879-886
- nicardipine bolus administration for therapy, 495-496
- nitroglycerin effect during coronary angioplasty, 497-500
- Left ventricular function (LVF)
- bisoprolol hemodynamic evaluation after coronary artery surgery, 629-632
- depression and proarrhythmia related, 519-520
- normal hemodynamic study of IV propionyl-L-carnitine for ischemic patients, 107-111
- Left ventricular hypertrophy, beta blockers in hypertension, 580-581
- Left ventricular pressure (LVP), extracellular potassium accumulation effect of calcium antagonists in rats, 1035-1040
- Left ventricular systolic pressure, propionyl-L-carnitine effect on isolated rat hearts, 78
- Leucocytes
- importance in reperfusion-induced injury, 230, 231
- and myocardial stunning, 857
- myocardial stunning and molecular mechanisms, 927-928
- neutrophils and myocardial stunning, 918-920
- Levomoprolol (ophthalmic), technico-commercial status, 546
- Lidocaine
- antiarrhythmic efficacy and proarrhythmic risk, 517, 519
- antiarrhythmic efficacy and proarrhythmic risk, 519, 523
- as coronary artery disease therapy for elderly, 450
- effect on triggered arrhythmias in dogs, 811-813, 815

- to abolish polymorphous ventricular tachycardia, 512
 - with disopyramide to affect use-dependent block of \dot{V}_{\max} , 791-798
 - with mexiletine to affect use-dependent block of \dot{V}_{\max} , 792
 - Lidoflazine, QT-interval prolongation, 522-523
 - Lipid peroxidation
 - calcium antagonists and myocardial stunning, 949-950
 - free radical effect on reperfusion-induced arrhythmias, 292-294
 - free radicals, 862, 865
 - free radicals trapped by PBN, 253, 255-256
 - and myocardial stunning, 903, 904
 - neutrophils and myocardial stunning, 916
 - occurring in stunned myocardium in dogs, 256, 261
 - Lipoproteins, human high- and low-density effect on reperfusion arrhythmias, 269-275
 - Lisinopril
 - threshold oral dose and most commonly effective doses, 775
 - vs. atenolol for mild to moderate essential hypertension, 775-781
 - Lithium, QT prolongation and polymorphic ventricular tachycardia, 523
 - Liver, encainide pharmacokinetics in cirrhosis patients, 733-738
 - Long-chain acylcarnitines, 67-75, 78, 79, 82
 - Long-chain acyl coenzyme A, 78, 79, 82
 - Long QT syndrome (LQTS), 203-205, 208-211
 - Low-density lipoproteins (LDL), promoting atherosclerosis, 269-275
 - L-SOD (liposomal-encapsulated SOD), 289-294
 - Lung disease, verapamil therapy for atrial fibrillation, 619
 - Lysophosphatidylcholine (LPC), 67, 68
 - Lysophosphoglycerides, 67, 74
 - Macrophage, cytotoxicity activity measured in OK432 test of effects on acute myocarditis, 472-474, 478
 - Magnesium
 - as component of cardioplegic solution, 729-732
 - erythrocyte content in patients with vasospastic angina, 677-680
 - non-aggravation of ventricular tachycardia supporting this as torsades de pointes first line of therapy, 509, 511-512
 - suppressing torsades de pointes when it is given intravenously, 505, 506
 - to inhibit the development of early after depolarizations, 202
 - Malondialdehyde, propionyl-L-carnitine
 - taurine amide lowering effect in heart tissue, 80
 - Malonic semialdehyde, conversion to acetyl-CoA, 11
 - Mannitol
 - intervention studied with arrhythmogenesis, 228
 - and myocardial stunning, 865
 - protective effect in reperfusion-induced arrhythmias of rat hearts, 227, 230
 - Maprotiline, QT prolongation and proarrhythmic risk, 523
 - MCI-154, end-stage heart failure, 965
 - Mechanical contractility, propionate dose-response relationship and myocardial oxygen consumption, 38, 40-42
 - Medroxalol, comparative beta blocker classification, 564
 - Mepindolol
 - characteristics, 579
 - technico-commercial status, 546
 - Mercaptopropionyl glycine (MPG)
 - enhancing recovery of the stunned myocardium, 250-254, 257
 - for myocardial stunning, 887
 - myocardial infarct size affected, 263
 - and myocardial stunning, 856-857, 859-860
 - to attenuate burst of radical production, 227-230
 - N-2-mercaptopropionyl-glycine, and myocardial stunning, 909, 943
 - Meta-analysis, clinical blood pressure trials, 983-984
 - Metabolism, calcium and other ions in reperfusion injury, 237-245
 - Methionine, intervention studied with arrhythmogenesis, 228, 232
 - 3-Methoxy-o-desmethyl encainide (MODE), effect on ADP/5-HT induced platelet aggregation and in canine intravascular thrombosis, 763-768
 - Methylcitrate, formation, 12
 - 2-Methylcitrate, formation, 11
 - Methyldopa
 - for hypertension, 583
 - long-term effects, 972
 - Methylmalonic-aciduria
 - carnitine action, 13, 14
 - causes, 11
 - Metipranolol, technico-commercial status, 546
 - Metolazone, effect on plasma renin activity, 745
 - Metoprolol, 565
 - antiischemic effects, 595
 - beneficial in heart failure, 594
 - blood pressure reduction, 606
 - cardioselective, 578
 - comparative studies with this as a reference agent, 545
 - compared to other beta blockers, 568
 - diastolic function effects, 595-596
 - as dilated cardiomyopathy long-term therapy, 463, 465-467
 - efficacy, 580
 - fatigue incidence, 569
 - and heart beta-adrenoceptor function, 555
 - heart failure studies, 590-592
 - inhibiting FABP leakage during hypoxia, 1021, 1023-1025
 - ischemic heart disease studies, 593
 - left ventricular hypertrophy, 581
 - lipophilicity advantageous for tracing, 1010
 - negative chronotropic effect, 600
 - plasma lipoprotein profiles altered, 569
 - receptor properties, 597
 - respiratory function, 582
 - tracer for pharmacokinetic analysis of coronary sinus retroinfusion, 1005-1010
 - with nicardipine for angina pectoris, 681
 - with nisoldipine for angina pectoris, 681
 - with tocainide for ventricular arrhythmias, 833
- Mexiletine
 - antiarrhythmic efficacy and proarrhythmic risk, 517, 519
 - effect on triggered arrhythmias in dogs, 809, 813, 815
 - for ventricular arrhythmias, 827-833
 - for ventricular premature beats, 835-840
 - side effects, 827, 831-832, 836-840
 - single-drug therapy in Japan for VPB's, 838
 - with disopyramide effects on \dot{V}_{\max} of guinea-pig ventricular muscles, 801-802
 - with disopyramide for ventricular arrhythmias, 827-833
 - with disopyramide to affect use-dependent block of \dot{V}_{\max} , 791, 793-796, 798
 - with flecainide effects on \dot{V}_{\max} of guinea-pig ventricular muscles, 801-803
 - with flecainide to affect use-dependent block of \dot{V}_{\max} , 791, 793, 795, 796-797
 - with lidocaine to affect use-dependent block of \dot{V}_{\max} , 792
 - with propranolol for ventricular arrhythmias, 829-830, 833
- Microvasculature, neutrophil contribution to myocardial stunning, 909-912
- Microvascular stunning, 918
- Milrinone
 - effect on neonatal pig hearts, 1011-1018
 - effect on triggered arrhythmias in dogs, 815
 - vs. digitals, 962

- Minoxidil, effect on blood pressure with beta blockers, 569
- Mitochondria
function affected by propionyl-L-carnitine on ischemic rabbit hearts, 57-64
propionyl-L-carnitine prevention of calcium overload, 57-58, 61-64
- Modulated receptor hypothesis, 803, 804
- Molsidomine
acute hemodynamic effects with ischemic cardiomyopathy, 155-156
SIN-1 effect on coronary arteries and peripheral vessels of sheep, 769-773
- Monensin, to increase reperfusion uptake of calcium, 242
- Monophasic action potential (MAP) technique, 205-206, 208
- Morgagni-Adams-Stokes syndrome, 172
- Moxonidine
for congestive heart failure, 972
for essential hypertension, 967-972
for myocardial ischemia, 972
- Multicenter Diltiazem Post-infarction Trial (MDPIT), 668, 672
- Multiple Risk Factor Intervention Trial, 984
- Multivessel disease, greater frequency in the elderly, 453
- Myasthenia gravis, disopyramide, 139
- Myocardial contractility
altered by naturally occurring substances, 22
effect of chronic administration of propionyl-L-carnitine, 18-22
- Myocardial function, neutrophil filtration effect, 909-912
- Myocardial hibernation, 878-879, 881-882, 887, 939-943
preferred term for myocardial stunning, 849-850
- Myocardial infarction
acute with increase in thromboxane A_2 , 273-275
antioxidant effect on limiting infarct size at time of reperfusion, 249, 259, 262-264
and calcium antagonists, 667-669
digitalis for atrial fibrillation contraindicated, 618
perindopril vs. chlorothiazide therapy effect on cardiac hypertrophy and sympathetic activity, 147-151
propionyl-L-carnitine having protective effect during ischemia, 74-75
propionyl-L-carnitine with tiapamil effect, 85-95
- Myocardial infarct size
determining myocardial infarction, 856
limitation using propionyl-L-carnitine with tiapamil, 85-95
vs. collateral blood flow in ischemic preconditioning, 937
- Myocardial ischemia, 314; *see also* Ischemic preconditioning
all possible outcomes, 939-943
alterations in levels of carnitine metabolites, 25, 28
basic, (327-332) 391-392
beta blockers, 561
calcium antagonist effects on extracellular potassium accumulation in rats, 1035-1040
calcium antagonists, (157-162) 367-368, (P482-496) 419-421
calcium antagonists' improvement of postischemic contractile function, 947-950
carnitine effect on electrophysiologic derangements, 67-75
cellular redox state, 862
duration related to postischemic recovery of function and functional performance, 302, 306-307
elderly patient treatment methods, 449
energy deficit causing rise in cytosolic calcium, 237-242, 244
enoximone given IV favorably, 694-695
exercise-induced, 942
fatty acid binding protein leakage during hypoxia, 1021-1026
and hypertension, 979
increase in free cytosolic calcium contributing to reperfusion arrhythmias, 250-253, 256-264
L-carnitine effect different from propionyl-L-carnitine, 14-15
metabolic consequences, 901-906
milrinone reversing contractile dysfunction result, 1011-1018
moxonidine, 972
and myocardial stunning, 867, 878-882, 884, 886, 887
myocardial stunning and molecular mechanisms, 925-926, 930
myocardial stunning and neutrophils, 909-912
neutrophils and postischemic dysfunction, 915-920
and nitrates, (82-93) 345-348
nitrates and other anti-ischemic drugs, (P348-P362) 397-399
nitroglycerin pretreatment effects on ischemic left ventricular dysfunction during coronary angioplasty, 497-500
propionate's ability leading to generation of energy in postischemic reperfusion phase, 7
propionyl-L-carnitine IV hemodynamic study in patients, 107-111
propionyl-L-carnitine, mitochondrial damage and long-chain Ac-CoA, 45
propionyl-L-carnitine protection against deterioration in rabbit hearts, 57-64
propionyl-L-carnitine protective effects in isolated rat hearts, 77-82
propionyl-L-carnitine with tiapamil effect, 87-91, 93-95
protective effect of propionyl-L-carnitine, 8, 11
reperfusion damage due to oxidative stress, 277-285
severity determining vulnerability to reperfusion-induced injury, 226-229, 231-232
superoxide dismutase (SOD) plus catalase improvement, 855-856, 858-859, 865
terminal nicorandil-Mg cardioplegia, 729-732
thromboxane A_2 as possible promoting factor, 273
UL-FS49 evaluated as potential treatment, 481, 486, 487
- Myocardial mitochondria, free radicals and radical scavenger effect, 289-295
- Myocardial necrosis, propionyl-L-carnitine with tiapamil effect on myocardial infarction, 87-89, 93-95
- Myocardial oxygen consumption
metabolic parameters for propionate effect, 38, 40-42
UL-FS49 effect on the canine heart, 486-487
- Myocardial protection, coenzyme Q_{10} for enhancement in coronary artery revascularization patients, 297-300
- Myocardial stunning
associated with reperfusion, 225, 229-230
beta-receptor antagonists in heart failure, 600
calcium antagonists, 947-950
calcium paradox, 861
calcium pathogenetic role, 891-892
calcium uptake and reperfusion, 895-898
causes, 853-855
clinical relevance, 877-887
contribution to ischemic preconditioning, 937-938
convalescence or reperfusion pathology, 860-861
damaging or protective to the myocardium, 939-943
decreased by low doses of calcium antagonists after reperfusion onset, 237, 242, 244-245
effect on recovery from reperfusion-induced injury, 226-227, 232
and free radicals, 856-860
genetic changes, 929-930
mechanical stunning, 854
mechanisms, 850, 903
milrinone effects in neonates, 1011, 1016-1017
molecular mechanisms, 925-930
neutrophil effect not important, 909-912

- neutrophils and postischemic dysfunction, 915-920
 and oxidant stress, 853-869
 oxygen paradox, 861
 prevention, 886-887
 reperfusion and oxygen-derived free radical effect, 250-262
 as reperfusion-induced injury, 854-855
 update, 849-850
 with reperfusion injury, 313-314
- Myocardial transferase, propionyl-L-carnitine as specific treatment, 5
- Myocarditis, OK432 preventive effects, 471-479
- Myocytes
 propionylcarnitine effect on canine hearts, 68-71
 propionyl-L-carnitine effect on isolated rat hearts, 78, 81, 82
- N-696 (beta-blocker), effect on triggered arrhythmias in dogs, 810, 813, 815
- N-acetylcysteine
 improved mechanical recovery after coronary occlusion, 257, 258
 improving post-ischemic contractile function recovery, 856
 myocardial infarct size affected, 263
- Nadolol, receptor properties, 597
- Nafazatrom, and myocardial stunning, 911
- Natural killer (NK) cell, percentage higher with encephalomyocarditis virus and OK432, 474, 477-479
- NCO-700, effect on triggered arrhythmias in dogs, 814
- Nebivolol (R67555)
 beta blocker therapy in the elderly, 582
 cardiac function, 580
 characteristics, 579
 comparative beta blocker classification, 564
 effect on blood lipids, 582
 influence on cardiovascular hemodynamics during postural changes and isometric exercise, 709-716
 nonadrenoceptor vasodilator, 570
 side effects, 582-583
 technico-commercial status, 546
- Neonate, milrinone effect beneficial for contractile dysfunction, 1011-1018
- Neurohumoral system, moxonidine effect on essential hypertension, 967-972
- Neuropeptides, and cardiovascular control, 119-127
- Neuropeptide Y (NPY)
 anatomic distribution, 124
 biochemistry, 124
 blood pressure effects, 125-126
 coexistence with catecholamines, 124-125
 concentration increased in hearts after stimulation by nicotine, 125
 effects on the heart, 126
 inhibiting presynaptic effects on nor-adrenaline release, 126
 interaction with other vasoconstrictors, 126
 mechanism of action, 126-127
 presynaptic effects, 126
 role in cardiovascular regulation, 119, 124-127
- Neutrophils
 contribution to myocardial stunning, 903, 904, 909-912, 915-920
 and coronary vascular resistance, 917-918
 depletion with myocardial stunning, 849, 850
 role in oxidative stress during reperfusion, 279
- Newman Keuls multiple comparison tests, 473, 490
- Nicainoprol, effect on triggered arrhythmias in dogs, 809, 813
- Nicardipine
 and myocardial stunning, 896
 reducing ambulatory blood pressure, 705
 slow-release adverse effects incidence, 650-652
 slow-release vs. nifedipine slow-release for hypertension with coronary heart disease, 647-653
 therapy for pulmonary edema during cardiac catheterization, 495-496
 to stimulate contraction of stunned myocardium, 950
- Nicorandil
 coronary effects in chronic conscious dogs, 131-137
 denitrated (SG-86), 137
 effect on triggered arrhythmias in dogs, 813, 815
 elimination half-life, 136
 mechanism of action, 131
 terminal nicorandil-Mg cardioplegia reducing extent of reperfusion injury, 727-732
- Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase reaction, 909
- Nicotine, stimulating isolated perfused hearts which show increased neuropeptide Y concentration, 125
- Nifedipine
 abolishing NPY effect in vascular tissues, 127
 beta blocker therapy in the elderly, 582
 diuretic effect, 659
 effect on triggered arrhythmias in dogs, 814
 efficacy, 580
 enhancing stunned myocardium function independent of hemodynamic blood flow effects, 259
 extracellular potassium accumulation in ischemic rats, 1035, 1037-1040
 for acute myocardial infarction, 667-669
 for hypertension, 975
 for unstable angina with acute myocardial infarction, 668
 hemodynamic interactions with celiprolol in angina pectoris, 681-686
 improving recovery of systolic and diastolic ventricular function after ischemia, 259
 improving systolic contraction, 947-950
 inhibiting FABP leakage during hypoxia, 1021, 1023, 1025
 more cost effective as treatment for hypertension, 164
 and myocardial stunning, 895-897, 943
 myocardial stunning and molecular mechanisms, 926
 nonspecific PN binding to human myocardial sarcolemma, 31-34
 slow-release adverse effects incidence, 650-652
 slow-release vs. nicardipine slow-release for hypertension with coronary heart disease, 647-653
 to relieve "stunning" by intracoronary administration during reperfusion, 245
- Nimodipine, protective effects against imipramine intoxication in rats, 489, 493-494
- Nipradilol
 characteristics, 579
 comparative beta blocker classification, 564
 nonadrenoceptor vasodilator, 570
- Nisoldipine
 effect on triggered arrhythmias in dogs, 814
 effect upon stress-induced renin-angiotensin-aldosterone activation evaluated, 643-646
 for reperfusion, 313
 and myocardial stunning, 896, 898
- Nitrates
 as coronary artery disease therapy for elderly, 450
 and myocardial ischemia, (82-93) 345-348, (P348-P362) 397-399
- Nitrate tolerance, effect on response to SIN-1 in human vena saphena magna, 457-461
- Nitrendipine
 ambulatory blood pressure monitoring results different, 705
 and myocardial stunning, 865
- p-Nitrobenzylthioinosine (NBMPR), 905
- Nitroglycerin (NTG)
 contractile response on human vena saphena magna, 457-461
 coronary effects in chronic conscious dogs, 131-137

- effect on triggered arrhythmias in dogs, 814
elimination half-life, 136
and hibernating myocardium, 941, 942
intravenous pretreatment effect on ischemic left ventricular dysfunction during coronary angioplasty, 497-500
Nitroprussiate, cross-tolerance with nitroglycerin, 460
Nitroprusside, acute myocardial infarction, 1050
Nondrug therapies, hypertension, 973-978
Noradrenaline (NA)
concentration increased with NPY after stimulation by nicotine, 125
concomitantly released with neuropeptide Y upon stimulation of guinea-pig vas deferens nerves, 125
perindoprilat effect during coronary artery occlusion and reperfusion in dogs, 1047-1048
vasoconstrictor effects potentiated by neuropeptide Y, 126
Norepinephrine
during hypoxia, 1025
metabolism elevated with infarction after perindopril or chlorothiazide therapy, 147, 149-151
No-reflow phenomenon, 230
myocardial stunning, 855
neutrophils and myocardial stunning, 918
NS-2 (AFD-21), effect on triggered arrhythmias in dogs, 811, 814
Nutrition, hyperinsulinemia and coronary heart disease, 1045
Octanoylcarnitine, protective therapeutic use, 8
OK432
preventive effect against diabetes mellitus, 471
preventive effects on murine acute myocarditis due to encephalitis virus, 471-479
protective effect against experimental herpes simplex virus infection, 471
OPC 88117 (antiarrhythmic drug), 809-810, 812, 813, 815, 816
Open-heart surgery, 942
glutathione oxidation and oxidative stress during reperfusion, 283-285
Organophosphate insecticides, poisoning causing torsades de pointes, 509
Organophosphate poisoning, QT prolongation and proarrhythmic risk, 524
Organophosphors, QT prolongation, 524
Oxidant stress, 314
and intracellular calcium, 865-869
and ion regulation, 863
and mitochondria, 865
and myocardial stunning, 853-869
reperfusion injury mechanism, 225, 227-229
and sarcolemma, 864-865
and sarcoplasmic reticulum, 863-865, 867
Oxidative metabolism in reperfused myocardium, 953
Oxidative stress, occurrence during reperfusion in animals and men, 277-285
Oxprenolol
intrinsic sympathomimetic activity, 566, 567
receptor properties, 597
Oxyfedrine
effect on coronary blood flow with coronary artery disease, 991-995
vs. propranolol, 994
Oxygen, toxic effects contributing to reperfusion damage, 277-285
Oxygen-derived free radicals
depressing myocardial function, 254-255
formation, sources, and myocardial defense mechanisms used during reperfusion, 277-285
and myocardial reperfusion injury, 249-264
and myocardial stunning, 849, 909, 912, 925, 927-928, 943, 949
Oxygen paradox
and myocardial stunning, 861
and reperfusion, 225-226
Oxypurinol
improved mechanical recovery after coronary occlusion, 257, 258
myocardial infarct size affected, 263
and myocardial stunning, 857
Palmitoylcarnitine
effect beneficial on ischemic hearts, 25
inhibition of sarcolemmal ATPase activity, 26-29
pathogenic role in inducing cardiac dysfunction, 25
protecting rat heart against ischemia, 8
vs. propionyl-L-carnitine, 5
Paroxysmal supraventricular tachycardia, aprindine and verapamil combination therapy, 819-824
PBN. See Alpha-phenyl *N*-tert-butyl nitron
Penbutolol
hemodynamic effects, 606
ischemic heart disease studies, 593
receptor properties, 597
technico-commercial status, 546
Pentacaine (ME3202), 810, 813
Peptides, role in cardiovascular regulation, 119-127
Percutaneous transluminal coronary angioplasty (PTCA)
acute myocardial infarction, 1050
in elderly patients, 452-453
and myocardial stunning, 879, 880
nitroglycerin pretreatment effects, 497-500
revascularization procedure used after reperfusion-induced arrhythmia in dogs, 289-290
Percutaneous transluminal coronary recanalization (PTCR), revascularization procedure used after reperfusion-induced arrhythmia in dogs, 289-290
Perindopril, vs. diuretic therapy effect after myocardial infarction in rats, 147-151
Perindoprilat, effect lacked during coronary artery occlusion and reperfusion in dogs, 1047-1048
Peripheral vascular disease, 568
Peripheral vasodilation, propionyl-L-carnitine effects on anesthetized dogs, 48, 51, 53, 55
Peroxidase
and myocardial stunning, 856
protective effect in reperfusion-induced injury, 231
Pharmacodynamics, elderly and coronary artery disease treatments, 450
Pharmacokinetics
encainide in patients with cirrhosis, 733-738
enoximone hemodynamic and antiischemic effects in coronary artery disease, 689-695
propionyl-L-carnitine chronic administration effect on rabbit hearts, 18-22
Phenothiazines, inducing torsades de pointes, 505
Phenoxybenzamine
antiarrhythmic effect, 987
vasodilation induced, 607
Phentolamine, 126
as adrenergic blocker during test of hemodynamic effects of PLC, 46
Phenylephrine, neuropeptide Y effect on pressor response, 126
 α -Phenyl *N*-tert-butyl nitron, to attenuate burst of radical production, 227-230
Phenytoin, effect on triggered arrhythmias in dogs, 810, 813-815
Pheochromocytoma, 561, 596
beta blocker therapy for AF, 619
neuropeptide Y contributing to characteristic blood pressure profile, 125
Phosphodiesterase (PDE)
inhibitors increasing myoplasmic calcium, 961-962, 965
selective inhibitor milrinone effect in neonatal pig hearts, 1011-1018
5-Phosphoribosyl-1-pyrophosphate, 905
Phosphoribosyl pyrophosphate (PRPP), and myocardial stunning, 902, 903

- Pilzicainide (SUN 1165), 811, 814, 815
 Pimobendane, end-stage heart failure, 962
 Pindolol, 556
 atrial fibrillation therapy, 619, 620
 beta blocker therapy in the elderly, 582
 blood pressure reduction, 568, 612
 causing heart failure, 568
 compared to other beta blockers, 568
 controlled studies in heart failure, 592
 downregulation for congestive heart failure, 594
 effect on central and peripheral hemodynamics, 567
 effect on triggered arrhythmias in dogs, 810, 813, 815
 efficacy, 580
 fatigue incidence, 568-569
 heart rate reduction, 606, 613
 intrinsic sympathomimetic activity, 566, 567
 lowering arterial pressure irrespective of plasma renin changes, 578
 receptor properties, 597
 Pirmenol, 810, 813
 Plasma aldosterone, xipamide hormonal effects in healthy men, 741-745
 Plasma-cell interactions, in atherogenesis, (P106-P118) 353-355
 Plasma concentration, cletiazem effect, 997-1002
 Plasmalemma
 effect of propionyl-L-carnitine on cardiomyocytes, 8
 protected by propionyl-L-carnitine during acidosis of the heart, 7
 Plasma membranes, effects of propionyl-L-carnitine, 8
 Plasma renin activity (PRA)
 benazepril effect on sino-aortic baroreceptor heart rate reflex, 748
 moxonidine effect on essential hypertension, 967-972
 xipamide effect on healthy men, 742-745
 Platelet aggregation, ADP/5-HT induced, and encaidine effect and canine intravascular thrombosis, 763-768
 Polyethylene glycol-conjugated superoxide dismutase (PEG-SOD), myocardial infarct size affected, 263
 Positron emission tomography
 acute myocardial infarction (book review), 1050
 to measure regional myocardial blood flow, 991, 992
 Post-infarct, verapamil or diltiazem benefit diminished or eliminated, 672
 Postischemic dysfunction, 942-943; *see also* Myocardial stunning
 attenuated by calcium antagonists, 947-950
 milrinone effects in neonate hearts, 1011-1018
 and myocardial stunning, 877-879, 884-885, 910, 915-920
 neutrophils and myocardial stunning, 910, 915-920
 Postural changes, nebivolol influence on cardiovascular hemodynamics, 709-716
 Potassium extracellular accumulation, calcium antagonists' effects in ischemic rat hearts, 1035-1040
 Potassium chloride, for treatment of torsades de pointes, 512
 Potassium-sparing diuretics, interaction with digoxin, 722-724
 Practolol
 heart failure studies, 590
 receptor properties, 597
 Prazosin
 antiarrhythmic effect, 987
 blood pressure reduction, 605
 hemodynamics effect, 610
 side effects, 971
 to inhibit calcium in reperfusion injury, 241
 total peripheral resistance index affected, 608, 612
 Prednisolone, immunosuppressive therapy for viral myocarditis, 477
 Prenalterol
 comparative beta blocker classification, 564
 partial agonist activity, 568
 Prenylamine, QT-interval prolongation and proarrhythmic risk, 523
 Presentation Young Investigators Award, (71-75) 341-342
 Pressor response, inhibited by benazepril and captopril in conscious normotensive dogs, 635, 639-640
 Pressure-controlled intermittent coronary sinus occlusion (PICSO), 1009
 Primary prevention, hypertension, 984
 Prinzmetal's angina, myocardial stunning, 849, 850
 Prizidilol
 blood pressure reduction, 612
 comparative beta blocker classification, 564
 hemodynamics effect, 610, 613
 side effects, 610
 total peripheral resistance reduced, 612
 Proarrhythmia
 a cause of death in 31% of cases having QT-interval prolongation, 515-518
 characteristics and prevalence after drug-induced QT prolongation, 518-524
 disopyramide with mexiletine combination therapy, 840
 predisposing factors, 518
 Probutol, improving post-ischemic contractile function recovery, 856
 Procainamide
 antiarrhythmic efficacy and proarrhythmic risk, 519, 520, 524
 antiarrhythmic efficacy and torsades de pointes, 524
 atrial fibrillation therapy, 621, 622
 effect on triggered arrhythmias in dogs, 811, 814, 815
 for ventricular tachyarrhythmias, 1008
 inducing torsades de pointes, 505-506, 509, 511
 single-drug therapy in Japan for VPB's, 838
 Procatrol, 556
 Pronethalol, 561, 566
 cardiac dimensions at rest and during exercise, 589
 resemblance to quinidine, 562
 Propafenone
 antiarrhythmic efficacy and proarrhythmic risk, 519
 atrial fibrillation therapy, 621, 622, 624
 effect on triggered arrhythmias in dogs, 810, 813, 815
 single-drug therapy in Japan for VPB's, 838
 Propionate
 biochemical reactions involved in metabolism, 7
 conversion to glucose in liver and kidney, 7
 disease of free CoA content, 14
 depressed myocardial function, 22
 effect in aerobic myocardium, and dose-response relationship, 37-42
 hemodynamic effect on anesthetized dogs, 51
 inert effect for ischemia and reperfusion in rabbit hearts, 63
 metabolic effects on rat liver, 13
 metabolism of, 5
 metabolism requirements, 7
 to correct metabolic disorders, 7-8
 Propionic acid, physiological importance and energy-rich derivatives, 7
 Propionic aciduria, 12
 activity of propionyl-CoA carboxylase low, 11
 carnitine action, 13, 14
 Propionylcarnitine, effect on electrophysiologic derangements elicited by myocardial ischemia and reperfusion in dogs, 67-75
 Propionylcarnitine taurine, preserved mechanical function during ischemia, 37
 Propionyl-CoA
 biochemical reactions involved in metabolism, 7
 inhibiting formation of succinate, 12
 interconversion to succinyl-CoA, 12
 metabolism of, 5

- precursors, 12
 product formation, 11-12
 stimulating the tricarboxylic cycle, 5
- Propionyl-CoA carboxylase
 deficiency, and urinary excretion of
 propionyl-L-carnitine, 7
 substrate oxidation related to dosage,
 42
- Propionyl-D-carnitine, effect on human
 endothelial cells, 100, 103
- Propionyl group, origin of carbon atoms,
 11
- Propionyl-L-carnitine (PLC)
 advantages over other anaplerotic
 agents, 14
 antiarrhythmic properties, 5
 biochemical profile, 7-8
 biochemical significance and role in
 cardiac metabolism, 11-15
 cellular permeability, 8
 diuretic effect, 51, 52
 dose-response action, 5
 effect beneficial on ischemic hearts,
 25-29
 effect of acute administration on left
 ventricular developed pressure,
 heart rate, and coronary perfusion
 pressure, 18-19
 effect of chronic administration on rab-
 bit hearts, 19-22
 effect on heart mitochondrial superox-
 ide formation, 81
 effect on human endothelial cells,
 97-104
 effect on L-type calcium channels in
 human heart sarcolemma, 31-35
 effect on mechanical function of iso-
 lated rabbit heart, 17-22
 effect on mitochondrial dysfunction
 due to lipid peroxidation, 28-29
 effect on plasmalemma of cardiomyo-
 cytes, 8
 effect on vascular endothelial cells, 8
 formula, 18
 hemodynamic changes induced in coro-
 nary artery diseased patients, 5
 hemodynamic changes induced in dogs,
 5
 hemodynamic study for intravenous
 administration in ischemic patients
 with normal LVF, 107-111
 increasing ATP production, 5
 increasing propionyl-CoA in mitochon-
 drial matrix, 7
 intravenous administration effects on
 hemodynamics in anesthetized dogs,
 45-55
 metabolic effects, 13
 metabolism of, 5
 possible effects on plasma membranes,
 8
 propionyl-CoA carboxylase deficiency,
 7
 protection against deterioration caused
 by ischemia and reperfusion, 57-64
 protection in myocardial ischemia and
 reperfusion, 37, 42
 protection of plasmalemma during aci-
 dosis of the heart, 7
 protective effect on myocardial in-
 farction in dogs, 85-95
 protective effects during ischemia and
 reperfusion in isolated rat hearts,
 77-82
 and stabilizing action of acylcarnitines
 upon biomembranes, 5
 taurine derivative, 8
 to correct metabolic disorders, 7-8
 utilization by muscle, 13-15
 utilized by heart tissue to stimulate
 tricarboxylic acid cycle, 11
 vs. L-carnitine, 5
 vs. palmitoylcarnitine, 5
- Propionyl-L-carnitine chloride, 31
- Propionyl-L-carnitine taurine amide
 (PTCA), effect on myocardial con-
 centrations of ATP and CP after
 ischemia and reperfusion, 79-82
- Propranolol, 556
 as adrenergic blocker during test of
 hemodynamic effects of PLC, 46
 antihypertensive agent, 577-578
 antihypertensive efficacy of vasodilator
 beta blocking, 570
 antiischemic effects, 595
 atrial fibrillation therapy, 619
 blood pressure effect, 568
 compared to other beta blockers, 568
 controlled studies in heart failure, 592
 effect on central and peripheral hemo-
 dynamics, 567
 effect on triggered arrhythmias in
 dogs, 810, 813
 for hypertension, 583, 983
 for treatment of torsades de pointes,
 512
 for ventricular arrhythmias, 827, 828,
 831, 832
 intolerance as beta blocker assessment
 criteria, 563
 ischemic heart disease studies, 593,
 595
 left ventricular hypertrophy, 581
 metabolic effects on diabetics, 571
 no improved arterial compliance, 581
 no intrinsic sympathomimetic activity
 (ISA), 566
 not blocking celiprolol vasodilator ac-
 tion, 570
 partial agonist activity, 565-567
 plasma lipoprotein profiles altered, 569
 receptor properties, 597
 resemblance to quinidine, 561-562
 respiratory effects, 583
 side effect of therapy, 577, 582
 total peripheral resistance, 569
 verapamil added when treating angina
 pectoris patients, 570-571
 vs. bisoprolol after coronary artery by-
 pass graft, 629-632
 vs. nebivolol, 570
 vs. oxyfedrine, 994
 vs. sustained-release diltiazem for hy-
 pertension, 701
 with mexiletine for ventricular ar-
 rhythmias, 827, 829, 830, 833
- Prostacyclin
 ratio to thromboxane A₂ significant for
 homeostasis of ischemic myocar-
 dium, 269-275
 neutrophils and myocardial stunning,
 919
- Prostaglandins, E₂ localization in subcel-
 lular rat heart fractions, 655-656
- Protein kinase, heart beta-adrenoceptor
 function, 550-551, 555, 556
- Pulmonary edema, nicardipine bolus ad-
 ministered therapy during cardiac
 catheterization, 495-496
- Pulmonary resistance, reduced by IV
 propionyl-L-carnitine, 107-111
- Purkinje fibers
 canine, depolarization and
 reperfusion-induced injury, 228
 QT prolongation by antiarrhythmic
 agents, 520, 522
- Quality adjusted life year (QALY),
 980
- Quality of life, beta blocker therapy in
 hypertension, 583
- Quinidine
 antiarrhythmic efficacy and proar-
 rhythmic risk, 519-520, 524
 effect on ECG of patient showing tor-
 sades de pointes, 204, 205, 209
 inducing torsades de pointes, 505-506,
 509-512
 pharmacologic treatment for atrial fi-
 brillation, 617, 621-623
 prolonging the QT interval to lead to
 "torsades de pointes," 515
 resemblance to other beta blockers,
 562
 single-drug therapy in Japan for
 VPB's, 838
 to produce experimentally early after-
 depolarizations, 201-202
 torsades de pointes and early after-
 depolarizations with intoxication,
 531, 534-536
- QT-interval
 causes for prolongation, 516
 drug-induced prolongation and drug
 arrhythmogenic hazards, 515-
 524
 formulas for the calculation of the up-
 per normal value at different heart
 rates, 517
 genesis, 516
 measurement of, 516
 mechanisms of ventricular repolariza-
 tion to determine, 516-518
 prolongation from quinidine combined
 with propranolol, 833

- prolongation caused by torsades de pointes associated with ventricular repolarization on ECG, 201-202
sotalol effect, 1029, 1031
- Radical scavengers**
reducing duration, frequency and severity of reperfusion-induced arrhythmias, 293-294
effect on reperfusion-induced arrhythmias in the canine heart, 289-295
- Ramiprilat, to ameliorate reperfusion arrhythmias, 244
- Rat hearts, calcium antagonist effects on extracellular potassium accumulation, 1035-1040
- Rauwolfia, for hypertension, 975
- Raynaud's phenomenon, 577, 582
beta blocker use, 568
- Receptor desensitization, heart beta-adrenoceptor function, 553-555
- Recombinant human superoxide dismutase (RH-SOD), effect upon myocardial protection, 301, 304-305, 307
- Recovery of V_{max} , FPL 13210 vs. disopyramide concentration-dependent electrophysiological effects, 139-146
- Recurrent AF for prophylaxis, digitalis for atrial fibrillation contraindicated, 618
- Reentry arrhythmias, prevented by propionyl-L-carnitine, 8
- Regional blood flow
adenosine biochemical and pharmacological effect, 903, 904, 906
myocardial stunning and molecular mechanisms, 928
oxyfedrine effect, 991-995
- Renin
gene expressed in the brain, 120
inhibited in experiment to test brain RAS and cardiovascular control, 121
nisoldipine effect on stress-induced activation in conscious pig, 643-646
- Renin-angiotensin system (RAS), and cardiovascular control, 119-121
- Reperfusion
and adenosine for myocardial stunning, 904-906
and antiarrhythmic drugs, (151-156) 365-366, (P363-P377) 401-403
associated with a burst of free radical generation after ischemia, 256-258
calcium antagonist improvement of postischemic contractile function, 947-950
calcium effect and effect of other ions, 237-245
calcium role in myocardial stunning, 891-892
cellular redox state, 862
coenzyme Q_{10} to enhance intraoperative myocardial protection in coronary artery revascularization, 297-300
cytosolic calcium increased, 895-898
four types of injury identified, 225, 227-231
free radicals' effect on ischemia reperfusion injury, 307
induced injury with a possible role for oxidant stress and its manipulation, 225-232
injury as fad, fashion, or fact, 223-224
injury progress and problems, 313, 315
injury reduced by terminal nicorandilMg cardioplegia, 727-732
ischemic preconditioning, 932-935, 937
milrinone effect in neonates, 1011-1018
and myocardial stunning, 854-855, 857-862, 865-868, 882, 885
myocardial stunning and molecular mechanisms, 926-930
myocardial stunning and neutrophils, 909-910, 918-920
oxidative stress in animals and men, 277-285
perindoprilat effect in dogs, 1047-1048
postischemic phase having energy generation by propionate and carnitine, 7
propionyl-L-carnitine protection against deterioration in rabbit hearts, 57-64
propionyl-L-carnitine stimulation of oxidation by fatty acids, 77-82
protection against ischemia by propionyl-L-carnitine, 8
Reperfusion damage, 277-285, 939-943
Reperfusion-induced arrhythmias, 854-855, 857-858, 860-862, 864, 867-869, 939
calcium uptake and myocardial stunning, 898
free radicals and radical scavenger effects in the canine heart, 289-295
lipoprotein effect on humans, 269-275
oxygen-derived free radicals, 249-250, 262
- Repolarization
associated with torsades de pointes, manifested as QT prolongation of ECG, 201-202
clinical conditions associated with abnormalities and torsades de pointes, 204, 205
Restitution of APD, FPL 13210 vs. disopyramide electrophysiologic effects, 139-145
Retroinfusion, coronary sinus, pharmacokinetic analysis using metoprolol as tracer, 1005-1010
Reversible injury, ischemic preconditioning, 933
Rheumatic mitral valve disease, 202
Rheumatic valvular disease, 620
Ribose, 905
Ro 40-5967, 672
- Rose bengal, inducing oxidant stress, 864, 865
- Ryanodine
aggravating triggered arrhythmias in dogs, 812
binding reduced by oxidant stress, 864, 868
effect upon myocardial protection, 301-307
not able to suppress early afterdepolarizations, 210
to diminish myocardial stunning, 895, 896
to inhibit calcium in reperfusion injury, 241
to suppress delayed afterdepolarizations, 210
- Ryanopine, for reperfusion, 313, 315
- SA 3212 (antiarrhythmic drug), 810, 813
- Salbutamol, 556
QT prolongation, 524
- Sarcolemma
calcium uptake increase, 897
long-chain acylcarnitine accumulation as effect of propionylcarnitine, 67-71, 73, 74
milrinone increasing intracellular calcium, 1017
myocardial stunning and molecular mechanisms, 926, 927
and oxidant stress, 864-865
propionyl-L-carnitine effect on L-type calcium channels in human hearts, 31-35
- Sarcolemmal ATPase, inhibition greatest by palmitoylcarnitine, 26-29
- Sarcoplasmic reticulum
calcium uptake increase, 897-898
end-stage heart failure, 965
ischemic preconditioning, 936
milrinone enhancing calcium release, 1017
and myocardial stunning, 902, 904
myocardial stunning and molecular mechanisms, 925, 926
and oxidant stress, 863-865, 867
- Sarcoplasmic reticulum ATPase, effect of carnitine derivatives less than that on sarcolemmal ATPase, 26-28
- Secondary blood cardioplegia, 731
- Semliki forest virus infection, macrophage activity, 478
- Serotonin
neutrophils and myocardial stunning, 918
resultant release at sites of coronary stenosis as component of unstable angina and myocardial infarction, 763-765
- Shay-Drager syndrome, 567
- Sick sinus syndrome
magnesium effect as therapy for torsades de pointes, 512
temporary pacemaker rather than anti-arrhythmic agents for AF, 620

- Silent ischemia, myocardial stunning, 850
 SIN-1 (3-morpholino-sydnominin)
 effect on coronary arteries and peripheral vessels of sheep, 769-773
 effect on human vena saphena magna studied, 457-461
 potent vasodilator and potent relaxant in coronary vessels in sheep, 772
 Single-drug therapy
 for ventricular arrhythmias, 827-833
 for ventricular premature beats, 835-840
 Sino-aortic baroreceptor reflex, benazepril effect, 747-750
 Smoking, and hypertension, 974, 976, 977
 Sodium channel
 alpha blockers, 987
 antiarrhythmic agent blocks, 813-816
 class I antiarrhythmic agent \bar{V}_{max} interactions as index of availability, 791-799
 mexiletine blocking effect, 803-804
 Sodium-calcium exchange, role in production of cytosolic calcium concentration in reperfusion injury, 237, 242
 Sodium-proton exchange, role in production of cytosolic calcium concentration in reperfusion injury, 237, 242
 Sequinolol
 characteristics, 579
 technico-commercial status, 546
 Sotalol
 atrial fibrillation therapy, 624
 hemodynamic effects of isomers on myocardium, 1027-1032
 inducing torsades de pointes, 509
 marketing of agent, 561
 QT prolongation, 524
 QT prolongation and antiarrhythmic efficacy and proarrhythmia risk, 521
 receptor properties, 597
 technico-commercial status, 546
 D-Sotalol
 hemodynamic effects on myocardium, 1027-1032
 effect on triggered arrhythmias in dogs, 813, 815
 DL-sotalol, cardiodepressive action, 1031, 1032
 L-sotalol, hemodynamic effects on myocardium, 1027-1032
 Spin trapping, 313
 alpha-phenyl *N-tert*-butyl nitron to enhance contractile recovery, 252-257
 electron paramagnetic resonance spectroscopy to measure oxygen free radicals, 279-280, 858, 860, 909
 and myocardial stunning, 904, 919
 Spironolactone, inotropic effect with digoxin, 719, 722-724
 Stable angina, and myocardial stunning, 879, 880, 887
 Stellate ganglion, activation inducing delayed afterdepolarizations (DADs), 209
 Streptokinase, intracoronary, and myocardial stunning, 882
 Stress, nisoldipine effect in induced renin-angiotensin-aldosterone activation, 643-646
 Strokes
 antihypertensive therapy, 973, 974
 incidence reduction, 980
 reduction by lowered blood pressure, 983
 risk reversal, 979
 Stunning. *See* Myocardial stunning
 Subcellular heart fractions,
 prostaglandin- E_2 localization in rats, 655-656
 Sublingual administration, ketanserin in hypertensive patients, 697-699
 Succinylcholine, QT prolongation, 524
 Sudden death
 beta blockers for ventricular arrhythmias, 828
 calcium antagonists vs. beta blockers for prevention, 673-674
 chlorothiazide combined with ACE inhibitor therapy for prevention, 151
 indirectly caused by calcium overload, 962
 magnesium myocardial content in cases with ischemic heart disease, 679
 13% of cases in study showed torsades de pointes, 509
 Sulfinpyrazone, 768
 Sulmazole
 effect on triggered arrhythmias in dogs, 815
 end-stage heart failure, 962
 Superoxide anions, exogenous sources administered to laboratory animals, 159
 Superoxide dismutase (SOD), 314
 effect on myocardial production of free radicals, 258
 enhancing recovery of function after reperfusion, 250, 252-255, 257-259, 261, 263
 induction of reperfusion measured by electron spin resonance, 289-294
 and myocardial reperfusion, 887
 and myocardial stunning, 855-859, 865, 905-906, 909
 myocardial stunning and molecular mechanisms, 927
 neutrophils and myocardial stunning, 919-920
 oxidative stress during reperfusion, 278-279, 281-283
 to attenuate burst of radical production, 227-228, 231
 Supraventricular arrhythmias, drug treatment, (P125-P139) 359-361
 Suxamethonium, QT prolongation, 524
 Sydnominines, molsidomine acute hemodynamic effects in patients with ischemic cardiomyopathy, 155-156
 Sympathetic activity, chronic increase after perindopril or chlorothiazide therapy after myocardial infarction in rats, 147
 Temperature, effect on calcium movement and pharmacologic protection upon postischemic recovery, 301, 306, 307
 Tenormin, for hypertension, 975
 Tension-time index (TTI), propionyl-L-carnitine IV hemodynamic effects on anesthetized dogs, 48
 Tertatolol
 antihypertensive mechanism, 580
 characteristics, 579
 comparative beta blocker classification, 564
 effect on blood lipids, 582
 technico-commercial status, 546
 Terbutaline, 565
 Terminal cardioplegia, 731
 with nicorandil and magnesium to reduce reperfusion injury, 727-732
 Tetrodotoxin, 517, 520-521
 Thiazide, for hypertension, 983-984
 Thioridazine
 inducing torsades de pointes, 509, 512
 QT-interval prolongation and proarrhythmic risk, 523
 Thoracotomy, neuropeptide Y and noradrenaline plasma levels increased, 125
 Three-vessel disease
 greater frequency in the elderly, 450, 451, 453
 oxyfedrine effect, 992
 Thrombolysis
 and antiplatelet agents, (13-18) 327-328, (P178-P192) 373-375
 myocardial stunning, 943
 Thrombosis, encainide inhibition in dog coronary arteries, 763-768
 Thromboxane, neutrophils and myocardial stunning, 918-919
 Thromboxane A_2 , prostacyclin ratio significant for homeostasis of ischemic myocardium, 269-275
 Thyrotoxicosis, beta blocker therapy for AF, 619
 Tiapamil, with propionyl-L-carnitine for protective effect on myocardial infarction in dogs, 85-95
 Tilisolol
 characteristics, 579
 technico-commercial status, 546
 Timolol
 antiischemic effects, 595
 blood pressure reduction, 606, 607
 compared to other beta blockers, 568
 heart rate reduction, 613
 left ventricular hypertrophy, 581

- receptor properties, 597
total peripheral resistance, 612-613
Tissue distribution, clentiazem increasing retention, 997
Tocainide, antiarrhythmic efficacy and proarrhythmic risk, 519
effect on triggered arrhythmias in dogs, 811-815
with metoprolol for ventricular arrhythmias, 833
Tocopherol, exogenous sources administered to laboratory animals, 159
 α -Tocopherol, as antioxidant defense mechanism, 231
Tolazoline, antiarrhythmic effect, 987
Tolerance, molsidomine metabolite SIN-1 effect on sheep, 769-773
Torsades de pointes (TDP)
amiodarone-associated, 522
arrhythmia vs. syndrome definitions in light of Lambeth Conventions, 191-199
associated with ventricular repolarization of ECG, manifested as QT prolongation, 201-202
atrial electrical activity, 182
causes, 194
clinical conditions associated with repolarization abnormalities and torsades de pointes, 204
definition (etiology) controversy, 194-196, 198-199
delayed repolarization syndrome, 191, 198, 199, 202
dispersion of refractoriness, 204-205
double pointes, 178, 180
drugs inducing this condition, 509-510
and early afterdepolarizations, 531-536
electrocardiographic description, 171-182
electrophysiologic mechanisms involved in development, 203-211
mechanism of perpetuation, giving electrocardiographic aspect of progressive change and spontaneous resolution, 167-168
mise à l'unisson, 174
patient characteristics and clinical features, 509
pattern of initiation, 205
prevention, 509-512
procainamide-induced, 520
prolonged repolarization-dependent excitation, 208
quinidine effect on ECG, 204, 205, 209
reason for discontinuing disopyramide for ventricular premature beats, 836, 837
terminal complex, 180
terminology and history, 505-506
therapy, 509-512
Total peripheral resistance (TPR), 567-569, 580
beta blocker therapy, 605-613
hypertensive patients requiring drug treatment, 605
Total peripheral vascular resistance (TPVR), nebivolol effect, 709-710, 712, 714-716
Total systemic vascular resistance, amiloride addition to digoxin, 721
Transesophageal atrial pacing, to assess paroxysmal supraventricular tachycardia with aprindine and verapamil therapy, 819-824
Transplantation (cardiac), and myocardial stunning, 879, 883-884, 887
Trapidil, 814
Treppe effect, 961
Triamterene, for hypertension, 975, 983
Tricarboxylic acid cycle, stimulated by exogenous propionyl-L-carnitine in heart tissue, 11
Triggered arrhythmias, 518
antiarrhythmic drug effects on canine ventricular arrhythmia models, 805-816
from early afterdepolarizations to explain torsades de pointes features, 536
reperfusion-induced injury, 228
responsible for torsades de pointes, 203, 204, 206-208
Trimazosin
blood pressure reduction, 605
total peripheral resistance index affected, 608
Trimetazidine (TMZ)
effect on triggered arrhythmias in dogs, 814
for angina pectoris and hemodynamic changes, 1043-1044
Tumor necrosis factor, neutrophils and myocardial stunning, 916-917
TYB-3823, 810, 813
UL-FS49, effect on isolated blood-perfused canine heart, 481-487
Umbilical vein, damaged in humans as result of D-glucose and glucose oxidase in test of propionyl-L-carnitine effect, 99-100
Unstable angina, 942, 943
and myocardial stunning, 229, 849, 850, 879-882, 884, 887
serotonin and platelet aggregation, 763, 767
with coronary bypass surgery in elderly, 451
Urapidil
effect on action potentials in guinea-pig ventricular myocardium, 987-990
technico-commercial status, 546
Urinary kallikrein excretion, xipamide hormonal effects in healthy men, 741, 743-745
Use-dependent block
class I antiarrhythmic agent effects on maximum rate of depolarization of guinea-pig papillary muscle action potentials, 791-799
class I antiarrhythmic agent effects on V_{max} of guinea-pig ventricular muscles, 801-804
Vagally induced atrial fibrillation, digitalis for atrial fibrillation contraindicated, 618
Variant angina (VA)
magnesium content of erythrocytes in patients, 677-680
and myocardial stunning, 881
Vascular stunning, 918
Vasodilators
milrinone beneficial to neonates with contractile dysfunction, 1011-1012, 1016-1018
via terminal cardioplegia, 731
Vasopressin
QT prolongation and proarrhythmic risk, 524
role in cardiovascular regulation, 119-121
Vasotec, for hypertension, 975
Vena saphena magna
dipyridamole effect on the response to SIN-1, 457-461
nitrate tolerance effect on the response to SIN-1, 457-461
Venous oxygen saturation, myocardial stunning and molecular mechanisms, 928
Ventricular arrhythmias
antiarrhythmic drug effects on canine models, 805-816
combination antiarrhythmic treatment, 827-833
prevented by calcium antagonists, 667
relationship between it and free fatty acid elevation and calcium in perfused rat hearts, 753-760
treatment, (140-145) 363-364
Ventricular fibrillation (VF)
as a principal cause of sudden cardiac death, 191
calcium antagonists in therapy, 671-674
ECG when induced by digitalis plus calcium administration, 208
electrocardiographic description, 186-190
most serious ventricular tachyarrhythmia manifestation, 191, 193, 195-199
reperfusion-induced, 227
torsades de pointes and early afterdepolarizations, 533
Ventricular fibrillation threshold (VFT), for measuring free fatty acid level relationship to ventricular arrhythmias in rats, 753-760
Ventricular premature beats (VPBs), disopyramide and mexiletine combination therapy, 835-840

- Ventricular premature complexes (VPCs), antiarrhythmic agent combination therapy, 828-833
- Ventricular repolarization, 516-518
- Ventricular tachyarrhythmias
- ECG-based classification scheme, 192-199
 - least serious tachyarrhythmia, 191, 193, 195-199
 - mechanism-based classification scheme, 191-192
 - nomenclature, 193-194
- Ventricular tachycardia
- disopyramide with mexiletine combination therapy, 840
 - warning sign of torsades de pointes where magnesium is ineffective, 511-512
- Verapamil
- abolishing NPY effect in vascular tissues, 127
 - allowing reperfusion recovery, 245
 - ambulatory blood pressure monitoring results different, 705
 - beneficial effect, 669
 - compared to propionyl-L-carnitine for ischemic protection, 31
 - effect on triggered arrhythmias in dogs, 810-812, 814
 - extracellular potassium accumulation in ischemic rats, 1035, 1037-1040
 - for acute myocardial infarction, 667-669
 - for ischemic heart disease with myocardial infarction, 667-668
 - improving recovery of systolic and diastolic ventricular function after ischemia, 259
 - improving systolic contraction, 947-950
 - and myocardial stunning, 895-897
 - negative inotropic effects with left ventricular failure, 671-673
 - perfused in experiment measuring palmitic acid and VF threshold in rat hearts, 755-756, 758-760
 - pharmacologic treatment of atrial fibrillation, 617-624
 - protective effects against imipramine intoxication in anaesthetized rats, 489-494
 - with aprindine for tachycardia, 819-824
- DL-Verapamil, effect upon myocardial protection, 301-305, 307
- Veratrin, QT prolongation and proarrhythmic risk, 524
- Vesnarinone, 815
- Vincamine, 523
- Visacor, 606
- Wilcoxon's nonparametric signed rank test, 483
- Wolff-Parkinson-White syndrome
- apiridine with verapamil combination therapy for tachycardia, 819-820, 823, 824
 - atrial fibrillation, 617-618, 620, 622-624
- Working pig hearts, propionate dose-response relationship in myocardial oxygen consumption, 37, 42
- Working rat hearts, 270
- propionate dose-response relationship in myocardial oxygen consumption, 38, 40-42
- World Health Organization, 975, 976, 980, 981
- "hypertension" defined, 984
- World Hypertension League, 978
- Xamoterol, 556
- antiischemic effects, 595
 - beneficial effects in heart failure, 594
 - cardiac function, 580
 - causing heart failure, 568
 - characteristics, 579-580
 - effect on blood pressure, 567
 - for treatment of chronic heart failure, 545
 - heart size reduced, 601
 - receptor properties, characteristics, and effects, 596-598
 - suitable for treatment of patients with heart failure, 568
- Xamoterolol, partial agonist activity, 567-568
- Xibenolol, technico-commercial status, 546
- Xipamide, hormonal effects in healthy men, 741-745
- YM 16151-1, comparative beta blocker classification, 564
- Yohimbine, antiarrhythmic effect, 987
- YUTAC, 810, 812, 813

